

Animal models to study AMPK

Benoit Viollet, Marc Foretz

► **To cite this version:**

Benoit Viollet, Marc Foretz. Animal models to study AMPK. Mario D. Cordero; Benoit Viollet. AMP-activated Protein Kinase, 107, Springer International Publishing, 2016, Experientia Supplementum, 978-3-319-43587-9. <10.1007/978-3-319-43589-3>. <<http://www.springer.com/gp/book/9783319435879#aboutBook>>. <inserm-01352196>

HAL Id: inserm-01352196

<http://www.hal.inserm.fr/inserm-01352196>

Submitted on 5 Aug 2016

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Copyright}

Animal models to study AMPK

Benoit Viollet^{1,2,3} and Marc Foretz^{1,2,3}

¹ INSERM U1016, Institut Cochin, Paris, France

² CNRS UMR 8104, Paris, France

³ Université Paris Descartes, Sorbonne Paris Cité, Paris, France

Correspondence: Benoit Viollet, Institut Cochin, Inserm U1016, CNRS UMR8104, Université Paris Descartes, 24 rue du faubourg Saint Jacques 75014 Paris, France. Phone + 33 1 44 41 24 01, Fax + 33 1 44 41 24 21, e-mail: benoit.viollet@inserm.fr

Running title: AMPK animal models

Keywords: AMPK-activated protein kinase; animal models; transgenic animals; energy metabolism; pharmacological drugs; therapeutics.

Abstract

AMPK is an evolutionary conserved energy sensor involved in the regulation of energy metabolism. Based on biochemical studies, AMPK has brought much of interest in the recent years due to its potential impact on metabolic disorders. Suitable animal models are therefore essential to promote our understanding of the molecular and functional roles of AMPK but also to bring novel information for the development of novel therapeutic strategies. The organism systems include pig (*Sus scrofa*), mouse (*Mus musculus*), fly (*Drosophila melanogaster*), worm (*Caenorhabditis elegans*) and fish (*Danio rerio*) models. These animal models have provided reliable experimental evidence demonstrating the crucial role of AMPK in the regulation of metabolism but also of cell polarity, autophagy and oxidative stress. In this chapter, we update the new development in the generation and application of animal models for the study of AMPK biology. We also discuss recent breakthroughs from studies in mice, fly and worms showing how AMPK has a primary role in initiating or promoting pathological or beneficial impact on health.

Introduction

AMP-activated protein kinase (AMPK) is widely accepted as a sensor of cellular energy balance (Hardie 2014). At the cellular level, AMPK promotes ATP producing catabolic pathways, while simultaneously inhibiting ATP consuming anabolic pathways. At the organismal level, AMPK integrates stress responses such as exercise as well as nutrient and hormonal signals to control whole body energy expenditure and substrate utilization. As such a potent regulator of cellular and whole body metabolism, AMPK has become the focus of great deal of attention and appeared as an obvious target for treatment of metabolic disorders such as obesity and type 2 diabetes (Winder and Hardie 1999). In several rodents models of diabetes and obesity, pharmacological activation of AMPK results in the remodeling of a wide range of metabolic pathways and have led to substantial improvement of disease outcome (Buhl et al. 2002, Halseth et al. 2002, Song et al. 2002, Cool et al. 2006, Fullerton et al. 2013). In parallel with rapid scientific discovery in cell-free and cellular systems, the development of animal models has been instrumental to the expanding field of AMPK (Viollet et al. 2009). Over the last decade, knockout (KO) mouse models for the different AMPK subunit isoforms as well as transgenic mouse models overexpressing loss of function or gain of function AMPK mutants have been developed to better understand the impact of AMPK on metabolic health and disease and have largely contributed to expand our knowledge on the relevance of AMPK in human disease (**Figure 1**). Conditional targeting approaches are now at the forefront of mechanistic studies to investigate the relevance and specificity of AMPK in the homeostasis of multiple organs. These mouse models are also critically important for pre-clinical translational studies and early stage clinical investigation to progress. In addition, the use of model organisms such as *Saccharomyces cerevisiae* (yeast) [See chapter AMPK in yeast: the SNF1 (sucrose non-fermenting 1) protein kinase complex], *Drosophila melanogaster* (fly) [See chapter The role of AMPK in *Drosophila melanogaster*] and *Caenorhabditis elegans* (roundworm) [See chapter 5'-AMP-Activated Protein Kinase Signalling in *Caenorhabditis elegans*] has played a key role in delineating the physiological role of AMPK pathway and has been instrumental to provide novel information on the biology of AMPK system (**Figure 1**). These various models helped to expand the paradigm of AMPK as a metabolic sensor and showed that AMPK has broad

effects on cellular function, regulating cell growth, autophagy, oxidative stress and cell polarity.

1- Naturally occurring mutations

Many genetically engineered animal models have been generated to investigate the physiopathological role of AMPK, but understanding of AMPK function has been also greatly advanced by studies of naturally occurring mutations in AMPK genes (**Figure 1**). These mutations are apparently fairly rare but can result in pronounced pathological changes (Milan et al. 2000, Blair et al. 2001, Gollob et al. 2001, Arad et al. 2002). Naturally occurring mutations have been initially characterized in the pig *PRKAG3* gene and the human *PRKAG2* gene (encoding the $\gamma 3$ and $\gamma 2$ -subunit of AMPK, respectively) and are associated with abnormally high glycogen accumulation that results in pathological changes to skeletal and cardiac muscle (Milan et al. 2000, Blair et al. 2001, Gollob et al. 2001, Arad et al. 2002). Later, a mutation in human *PRKAG3* gene has been identified in association with an increase in skeletal muscle glycogen content and a decrease in intramuscular triglyceride (Costford et al. 2007).

• 1-1- Human and pig *PRKGA3* gene mutations and related mouse models

In 2000, a naturally occurring mutation in the $\gamma 3$ -subunit of AMPK, primarily expressed in white skeletal muscle (glycolytic, fast-twitch type II), was identified in purebred Hampshire pigs by a positional cloning approach (Milan et al. 2000). A non-conservative substitution (R200Q) was the causative dominant mutation in RN⁻ (in French *Rendement Napole* for Napole yield) pigs. Animals carrying the RN⁻ mutation are characterized by a marked increase of the glycogen content in glycolytic skeletal muscle leading to low muscle pH 24h post mortem due to anaerobic glycogen degradation, poor water-holding capacity, and low processing yield in the production of cured and cooked ham (Enfalt et al. 1997). Glycogen accumulation in skeletal muscle is consistent with the upregulation in the activity of UDP-glucose pyrophosphorylase and glycogen branching enzyme, two key enzymes regulating glycogen synthesis (Estrade et al. 1994, Hedegaard et al. 2004). R200Q carriers are also characterized by a higher oxidative capacity in white skeletal muscle fibers (Estrade et al. 1994). Conversely, additional naturally occurring missense mutations (T30N, G52S and V199I) were also identified in the *PRKAG3* gene from

Western and Chinese indigenous pig breeds associated with an opposite phenotype compared to the RN⁻ pigs, resulting in reduced skeletal muscle glycogen content and additive effect on meat quality traits (Ciobanu et al. 2001, Huang et al. 2004).

Strong support for the causative nature of the R200Q mutation in the elevated skeletal muscle glycogen content has been provided by transgenic mouse models overexpressing primarily in white skeletal muscle the mouse $\gamma 3$ R200Q mutant form (in these studies, the R200Q missense mutation is designated R225Q as the start methionine codon proposed by Cheung *et al.* (Cheung et al. 2000) is used) (**Table 1**). Muscle-specific transgenic mouse lines overexpressing the AMPK $\gamma 3$ R225Q mutant under the control of either the myosin light-chain or the muscle creatine kinase promoter/enhancer were generated and resulted in significant increases in skeletal muscle glycogen, replicating the pig RN⁻ phenotype (Barnes et al. 2004, Yu et al. 2006) (**Table 2**).

The R200Q missense mutation occurs within the cystathionine β -synthase domain 1 (CBS1) of the regulatory AMPK $\gamma 3$ subunit, which is involved in the binding of the allosteric activator of the kinase, AMP. Originally, there was great controversy over the impact of the R200Q mutation on AMPK activity. It was initially reported that the activity of AMPK was reduced in muscle extracts from RN⁻ pigs both in the presence and absence of AMP (Milan et al. 2000). In resting muscle from AMPK $\gamma 3$ R225Q mutant mice, AMPK activity was found to be decreased (Yu et al. 2006) or unaltered (Barnes et al. 2004). However, reduced AMPK activity could reflect the potential feedback inhibition of glycogen overload on AMPK activation (Milan et al. 2000, Jorgensen et al. 2004). Thus, to evaluate the impact of CBS domain mutation, activity of $\alpha 2\beta 2\gamma 3^{\text{R225Q}}$ trimer was measured from heterotrimeric complexes purified from transiently transfected COS cells and resulted in a higher basal AMPK activity and loss of AMP dependence (Barnes et al. 2004). Nevertheless, question remains on the mechanisms regulating AMP-independent activity of the AMPK $\gamma 3$ R225Q mutant (Lindgren et al. 2007), indicating that more detailed functional studies are needed to precisely define the nature of this mutation in the CBS domain of AMPK $\gamma 3$. Interestingly, a homologous mutation to the RN⁻ mutation found in pigs has been identified in the human PRKAG3 gene from genetic studies of lean and obese human populations (Costford et al. 2007). Subjects bearing the AMPK $\gamma 3$ R225W mutation exhibit increased skeletal muscle glycogen content, indicating conserved AMPK $\gamma 3$ function across mammalian species (Costford et al. 2007). The AMPK $\gamma 3$ R225W mutation is associated with increased activity of AMPK in

differentiated muscle cells derived from *vastus lateralis* biopsies (Costford et al. 2007). Furthermore, it should be noted that introduction of the equivalent mutation R70Q in AMPK γ 1 and R302Q in AMPK γ 2 also caused a marked increase in AMPK activity (Gollob et al. 2001, Hamilton et al. 2001, Yavari et al. 2016). More recently, studies with exercise trained RN γ pigs have shifted towards the recognition that γ 3 R200Q mutation is a gain-of-function mutation, which results in hyperaccumulation of glycogen due to increased influx of glucose and, enhanced endurance exercise capacity (Granlund et al. 2010, Granlund et al. 2011). Increased glycogen level is not due to impaired glycogen utilization as glycogen breakdown is similar after exercise in carriers and non-carriers of the RN γ mutation (Granlund et al. 2010). These results are consistent with the finding that pigs carrying the R200Q mutation show increased signaling response of Akt and phosphorylation of its substrate, AS160, a higher capacity for phosphorylation of glucose and, faster muscle glycogen resynthesis after exercise (Granlund et al. 2010, Essen-Gustavsson et al. 2011, Granlund et al. 2011). However, a slightly reduced basal and contraction-stimulated rates of glucose uptake was evidenced in transgenic AMPK γ 3 R225Q mutant mice (Barnes et al. 2004, Yu et al. 2006), suggesting that enhanced glycogen accumulation is not due to a single mechanism. The possibility that increases in total glycogen synthase activity contribute to elevated glycogen concentrations cannot be excluded (Yu et al. 2006). Other factors that could influence glycogen synthesis are the difference in the gene regulatory responses that facilitate metabolic adaptations. It has been shown that overexpression of AMPK γ 3 R225Q coordinates the transcription of genes important for glycolytic and oxidative metabolism (Nilsson et al. 2006) and leads to change in the adaptive metabolic response of glycolytic skeletal muscle by inducing mitochondrial biogenesis and function (Garcia-Roves et al. 2008). Accordingly, transgenic AMPK γ 3 R225Q mutant mice display a greater reliance on lipid oxidation and are protected from high fat diet-induced insulin resistance in skeletal muscle through increased fat oxidation (Barnes et al. 2004, Barnes et al. 2005). One consequence of increased fatty acid oxidation in AMPK γ 3 R225Q skeletal muscle could be the reduction of the demand for glucose oxidation via the Randle effect (Hue and Taegtmeyer 2009), inducing a glucose-sparing effect that drives glucose towards glycogen synthesis.

•1-2- Human PRKGA2 gene mutations and related animal models

Point mutations in the AMPK γ 2 subunit, encoded by the *Prkag2* gene, have been associated with a rare autosomal-dominant genetic disease of the heart in humans (Blair et al. 2001, Gollob et al. 2001, Gollob et al. 2001). Genetic defects in the *Prkag2* gene are characterized by a cardiac glycogen overload, ventricular pre-excitation (Wolff-Parkinson-White syndrome) and cardiac hypertrophy. One of the first human mutation identified occurred at residue 302, resulting in change of arginine to glutamine (R302Q), which is homologous to the R200Q *Prkag3* gene mutation in pigs (Milan et al. 2000, Gollob et al. 2001). Subsequently, identification of additional dominant mutations of PRKAG2 gene has been reported in families coupled with congenital hypertrophic cardiomyopathy and familial pre-excitation syndrome. However, distinct clinical onset and variability in clinical manifestations exist between the various PRKAG2 mutations (Porto et al. 2016). This phenotypic disparity may be a result of the specific effects of individual mutations on AMPK γ 2 activity and function. To date, missense mutations include G100S (Zhang et al. 2013), R302Q (Gollob et al. 2001, Arad et al. 2002), H383R (Blair et al. 2001), R384T (Akman et al. 2007), T400N (Arad et al. 2002), K485E (Liu et al. 2013), Y487H (Arad et al. 2005), N488I (Arad et al. 2002), E506K (Bayrak et al. 2006), E506Q (Kelly et al. 2009), H530R (Morita et al. 2008), R531G (Gollob et al. 2001), R531Q (Burwinkel et al. 2005), S548P (Laforet et al. 2006) and insertion of an additional leucine residue L351Ins (Blair et al. 2001). These mutations occur very selectively in strategic positions within the CBS motifs or in linker sequences between these motifs, but not in other parts of the AMPK γ 2 subunit. One interesting exception is the G100S mutation mapped into a non-CBS domain. However, it remains unclear if a mutation outside the CBS domains can indirectly changes the binding ability of CBS domains to AMP and ATP. Collectively, these data strongly suggest a specific connection between AMP and ATP binding and the different PRKAG2 mutations, supporting the notion that dysregulation of AMPK activity (gain- or loss-of-function) contributes to the development of the cardiomyopathy.

Consistent with a causative role of PRKAG2 in Wolff-Parkinson-White syndrome, heterozygous mice overexpressing mutant PRKAG2 alleles (R302Q, T400N, N488I, R531G) under the cardiac-specific α -myosin heavy chain (α -MHC) promoter develop pathological cardiac changes resembling the human PRKAG2 cardiomyopathy with significant glycogen accumulation, ventricular preexcitation and cardiac hypertrophy (Arad et al. 2002, Arad et al. 2003, Sidhu et al. 2005, Davies et al. 2006, Banerjee et al.

2007) (**Table 2**). In addition, transgenic zebrafish with cardiac specific expression of the G100S and R302Q mutations in PRKAG2 exhibit typical features of the human disease with cardiac hypertrophy and increased glycogen storage in the heart (Zhang et al. 2014). The PRKAG2 cardiac phenotype has been attributed to alterations in AMPK activity resulting from the AMPK γ 2 mutations. However, the action of the different PRKAG2 mutations on AMPK activity and sensitivity to AMP appears to be partially different, if not opposite (Daniel and Carling 2002, Scott et al. 2004). Transgenic mouse model with cardiac specific overexpression of the AMPK γ 2^{N448I} and AMPK γ 2^{T400N} mutations have been reported to increase AMPK basal activity (Arad et al. 2003, Banerjee et al. 2007), whereas the AMPK γ 2^{R302Q} and AMPK γ 2^{R531G} mutations results in the inhibition of AMPK (Sidhu et al. 2005, Davies et al. 2006). These discrepant findings could be related to a biphasic response of AMPK activity in response to the overexpression of PRKAG2 mutations (Banerjee et al. 2007, Folmes et al. 2009). Alteration in cardiac AMPK activity is possibly due to a feedback inhibition of the kinase activity by glycogen accumulation (Davies et al. 2006, Folmes et al. 2009), masking the consequences of human PRKAG2 mutations on AMPK activity. To confirm that increased AMPK activity is responsible for PRKAG2 cardiomyopathy, transgenic mice overexpressing AMPK γ 2^{N448I} and γ 2^{T400N} were crossbred with transgenic mice expressing a dominant negative form of the AMPK α 2 subunit, AMPK α 2^{D157A} (**Table 1**) in the heart to alter AMPK activity (Ahmad et al. 2005, Banerjee et al. 2007). Compound heterozygous mice have reduced cardiac AMPK activity and minimal cardiac dysfunction, demonstrating that activation of α 2-containing AMPK heterotrimeric complexes rather than α 1-containing complexes are responsible for the cardiac phenotype (Ahmad et al. 2005, Banerjee et al. 2007). Furthermore, studies using a transgenic mouse model expressing a human AMPK γ 2^{N488I} mutant protein under transcriptional control of a tetracycline-repressible α -myosin heavy chain promoter (**Table 1**) provide evidence that clinical manifestations of PRKAG2 cardiomyopathy are significantly reversed by the suppression of mutant AMPK activity after the onset of the disease (Wolf et al. 2008). This finding suggests that the appropriate pharmacological targeting of AMPK or its downstream effectors may help to improve the phenotypic expression of the disease. Compelling evidence now exists that aberrant increase of basal AMPK activity by PRKAG2 mutations results in global remodeling of the metabolic network in favor of glycogen storage (Zou et al. 2005, Luptak et al. 2007) (**Table 2**).

Thus, the metabolic consequences of chronic activation of AMPK in the absence of energy deficiency is distinct from those previously reported during stress conditions. In heart carrying a mutant *PRKAG2* allele, inappropriate activation of AMPK triggers an increase in both glucose uptake and fatty-acid oxidation, inducing, via the Randle effect, an inhibition of glucose oxidation leading to the storage of the exceeding glucose into glycogen. The mechanism of increased glucose uptake has been attributed to the upregulation of the sodium-dependent glucose co-transporter (SGLT) isoform SGLT1 but not facilitated-diffusion glucose transporter 1 (GLUT1) or GLUT4 in AMPK $\gamma 2^{T400N}$ transgenic mice (Banerjee et al. 2010). Confirmation of the role of SGLT1 in the phenotypic features of the *PRKAG2* cardiomyopathy has been demonstrated by the knockdown of cardiac SGLT1 in transgenic mice overexpressing the *PRKAG2* T400N mutation, which attenuates the cardiomyopathy phenotype (Ramratnam et al. 2014). Due to increased glucose uptake, the transgenic mice overexpressing the AMPK $\gamma 2^{N448I}$ mutation manifest high intracellular glucose-6-phosphate (G6P) levels, which contribute to the allosteric activation of glycogen synthase (GS) and enhanced glycogen synthesis (Luptak et al. 2007). By genetic inhibition of G6P-stimulated glycogen synthase activity, the pathological glycogen storage phenotype was rescued, providing definitive evidence for extensive remodeling of substrate metabolism and the causative role for high intracellular G6P in *Prkag2* cardiomyopathy (Kim et al. 2014). Surprisingly, elimination of excessive glycogen accumulation eliminated the ventricular preexcitation but not the cardiac hypertrophy phenotype, indicating that the abnormal cardiac growth is regulated by separate mechanisms. Recent studies indicate that AMPK $\gamma 2^{N448I}$ and AMPK $\gamma 2^{T400N}$ mutations stimulate hypertrophic signaling with activation of the transcription factors nuclear factor κB (NF- κB) and forkhead box O transcription factor (FoxO), and the mammalian target of rapamycin (mTOR) signaling pathway (Banerjee et al. 2010, Kim et al. 2014).

2- Genetically modified mouse models

Murine models have been widely used in biomedical research. Extensive similarities in anatomy, physiology and genetics have allowed numerous inferences about human biology to be drawn from mouse models. The recent development of conditional targeting approaches and the availability of numerous genetically modified mouse

models greatly facilitate functional studies. Important progress has been made during the last decade in the understanding of the pathophysiological function of AMPK, partly due to the generation of whole-body and conditional KO mouse models as well as tissue-specific transgenic mice (**Table 1**). These mouse models have made it possible to decipher the distinct physiopathological functions of the multiple AMPK isoforms and AMPK heterotrimer combinations.

•1-1- AMPK knock-out mouse models

Generation of whole-body deletion of each catalytic or regulatory AMPK subunits results in viable mice (**Table 1**). Of note, a mouse model of AMPK β 1 deletion using a gene trap approach resulted in severe brain developmental defect leading to postnatal death (Dasgupta and Milbrandt 2009). These mice express a fusion protein containing a AMPK β 1 N-terminal fragment (2-224) fused to β -galactosidase and may explain the abnormal brain development and not the loss of the AMPK β 1 subunit (Dzamko et al. 2010). Interestingly, targeted disruption of AMPK subunits is associated with distinct phenotypic abnormalities (Viollet et al. 2003, Barnes et al. 2004, Jorgensen et al. 2004, Dzamko et al. 2010, Steinberg et al. 2010, Foretz et al. 2011, Dasgupta et al. 2012). These diverse phenotypes could simply reflect isoform-preferred substrate phosphorylation between the combination of AMPK α 1- and AMPK α 2-containing heterotrimeric complexes, but a recent phosphoproteomic approach in cancer cells fails to identify specific targets for AMPK α 1 or AMPK α 2 (Schaffer et al. 2015). These data are rather suggestive of distinct tissue-specific contribution of the different isoforms in the control of AMPK activity and function. This is in line with the description of specific pattern of expression for AMPK α , AMPK β and AMPK γ isoforms between tissues (Stapleton et al. 1996, Thornton et al. 1998, Cheung et al. 2000). Indeed, the expression of AMPK β 1 and AMPK β 2 isoforms differ in a number of tissues, with AMPK β 1 highly expressed in liver and weakly expressed in skeletal muscle, whereas the opposite pattern is observed for AMPK β 2 (Thornton et al. 1998). Studies from AMPK β 1 $^{-/-}$ and AMPK β 2 $^{-/-}$ mice have highlighted the relative importance of these two isoforms in the liver and skeletal muscle, respectively (Dzamko et al. 2010, Steinberg et al. 2010). Another striking example of restricted expression of AMPK isoforms come from reports showing exclusive expression of AMPK α 1, but not AMPK α 2, in erythrocytes, macrophages and T cells (Tamas et al. 2006, Sag et al. 2008, Foretz et al. 2010). Mice lacking AMPK α 1 are

anemic and had markedly enlarged spleens (Foretz et al. 2010). Similar phenotypes are observed in mice lacking AMPK γ 1, the only AMPK γ isoform expressed in murine erythrocytes (Foretz et al. 2011). Studies of AMPK α 1-/- and AMPK γ 1-/- mice revealed that AMPK is required for erythrocyte homeostasis by regulating erythrocyte membrane elasticity (Foretz et al. 2010, Foretz et al. 2011) and autophagy-dependent mitochondrial clearance during erythrocyte differentiation (Wang et al. 2010). In addition, with the use of bone marrow-derived macrophages from AMPK α 1-/- and AMPK γ 1-/- mice, the regulatory role of AMPK in the macrophagic differentiation of monocytes (Obba et al. 2015) and the polarization of macrophages to an anti-inflammatory phenotype (Zhu et al. 2015) has been demonstrated. Support for a critical role of AMPK in the regulation of the pro-inflammatory/ anti-inflammatory balance in macrophage has been provided in previous studies using adoptive transfer of AMPK β 1-/- bone marrow in control recipient mice (Galic et al. 2011). It has been also established that AMPK is a key determinant of T cell effector responses by controlling T cell metabolism. AMPK α 1-deficient T cells display reduced metabolic plasticity *in vitro* as well as *in vivo* during viral and bacterial infections (Blagih et al. 2015). However, with the exception of these studies on erythrocytes, macrophages and T cells, analysis of the consequence of genetic deletion of one catalytic isoform should be done with caution, since compensatory increase in expression and activity of the remaining isoform can mask a particular phenotype. This has been clearly evidenced in primary culture of mouse proximal tubules from AMPK α 1-/- and AMPK α 2-/- mice, where adaptive up-regulation of the other AMPK α isoform fully compensate and can substitute for the other for ameliorating the response to metabolic stress (Lieberthal et al. 2013). Similarly, it has been reported that AMPK α 1 activity is higher in AMPK α 2-/- muscle as compared to control muscles, suggesting a compensatory effect (Jorgensen et al. 2004) (see below). In addition, overexpression of AMPK α 2 compensated for loss of AMPK α 1 and may explain the lack of phenotype in chondrocyte-specific ablation of AMPK α 1 (Yang et al. 2016). In attempt to generate full KO of AMPK, AMPK α 1-/- and AMPK α 2-/- or AMPK β 1-/- and AMPK β 2-/- mice have been crossed but combined disruption of AMPK isoforms is incompatible with life, indicating that AMPK is required during embryogenesis (Viollet et al. 2009, O'Neill et al. 2011). AMPK α 1-/- α 2-/- double knockout embryos die at ~10.5 days post-conception (B. Viollet, unpublished data). The recent development of tissue-

specific and conditional knockout technology has now allowed the generation of animal models completely lacking AMPK activity in a specific tissue (**Table 1**). Among the first tissues to be targeted, skeletal muscle-specific deletion of both AMPK α 1/AMPK α 2 and AMPK β 1/AMPK β 2 has been obtained by crossing AMPK α 1^{fl/fl} α 2^{fl/fl} and AMPK β 1^{fl/fl} β 2^{fl/fl} mice with transgenic mice expression the Cre recombinase under the control of the human skeletal actin and muscle creatine kinase promoter, respectively (O'Neill et al. 2011, Lantier et al. 2014).

•1-2- Insight from mouse models into AMPK-dependent stimulation of glucose uptake in skeletal muscle

Skeletal muscle contraction is associated with a dramatic increase in energy turnover rates that represents a major metabolic challenge. Since the first report on acute skeletal muscle AMPK activation in response to physical exercise in rodents (Winder and Hardie 1996) and later in humans (Chen et al. 2000, Fujii et al. 2000, Wojtaszewski et al. 2000), the role of AMPK in the adaptive changes in skeletal muscle has been a subject of intense research. During exercise, contracting skeletal muscle rapidly increases glucose uptake in an intensity-dependent manner to sustain the energy demand caused by increased ATP turnover. The idea that AMPK was involved in regulating glucose transport in skeletal muscle was supported by the observations that stimulation of glucose transport was achieved upon AMPK activation by AICAR (Merrill et al. 1997) and later by other pharmacological AMPK agonists such as Ex229/991 (Lai et al. 2014). The importance of AMPK in skeletal muscle glucose uptake has been investigated in genetically modified mouse models, including transgenic mice expressing naturally occurring mutation in the AMPK γ 3 isoform (**Table 1**). Muscles from knock-out mice (AMPK α 2^{-/-}, AMPK β 2^{-/-} and AMPK γ 3^{-/-}) or transgenic mice expressing a dominant negative form of AMPK α 2 in skeletal muscle (AMPK α 2-KD and AMPK α 2i) completely abolished *ex vivo* AICAR- and EX229/991-stimulated glucose uptake (Mu et al. 2001, Barnes et al. 2004, Jorgensen et al. 2004, Fujii et al. 2005, Steinberg et al. 2010, Lai et al. 2014). From these data, it has been suggested that contraction-stimulated glucose uptake is dependent on AMPK α 2 β 2 γ 3, the major heterotrimer activated by exercise in human muscle. However, the role of AMPK in contraction-stimulated glucose uptake remains controversial. In AMPK α 2^{-/-}, AMPK β 2^{-/-}, AMPK γ 3^{-/-}, AMPK α 2-KD and AMPK α 2i mice *ex vivo* contraction-stimulated glucose uptake is normal or only moderately reduced (Mu et al.

2001, Barnes et al. 2004, Jorgensen et al. 2004, Fujii et al. 2005, Steinberg et al. 2010). Similarly, the role of AMPK in exercise-induced skeletal muscle glucose transport *in vivo* is not clear. While one study reported no alterations in exercise-induced glucose transport (Maarbjerg et al. 2009), a clear reduction was shown in another study (Lee-Young et al. 2009). These discrepancies are probably due to redundancy of signaling coming from residual AMPK activity in these mouse models where only a single AMPK isoform is genetically altered/deleted and is probably sufficient to increase glucose uptake during muscle contractions. AMPK α 1 subunit is still present in AMPK α 2 $^{-/-}$ and AMPK α 1 activity can be detected in AMPK α 2-KD mice and may sustain alone the coordination of muscle metabolism and adaptation to exercise. To circumvent this problem, conditional muscle-specific knockout of both AMPK α and AMPK β subunits have been generated. Deletion of AMPK β 1 and AMPK β 2 isoforms inhibited both contraction- (*ex vivo*) and exercise- (*in vivo*) induced glucose transport in skeletal muscle (O'Neill et al. 2011), while the deletion of both AMPK α 1 and α 2 showed reduced contraction-stimulated glucose uptake in soleus but not EDL muscle (Lantier et al. 2014). Consistent with the idea of functional redundancy between isoforms, it should be noted that mice lacking the AMPK β 2 subunit specifically in skeletal muscle had normal glucose uptake despite reductions in AMPK activity of more than 90% (O'Neill et al. 2011). Altogether, these findings support the notion that AMPK is necessary to achieve the effects of exercise on muscle glucose transport. The mechanism underlying AMPK-dependent contraction-induced stimulation of glucose uptake has been described to act through the phosphorylation of the Rab GTPase activating protein Tre-2/BUB2/ cdc 1 domain (TBC1D) 1. TBC1D1 has several common contraction and AICAR responsive phosphorylation sites that are blunted in AMPK α 2 $^{-/-}$, AMPK γ 3 $^{-/-}$, AMPK α 2-KD and AMPK α 2i mice (Treebak et al. 2006, Pehmoller et al. 2009, Vichaiwong et al. 2010). This has been further supported by recent findings showing a reduction in TBC1D1 phosphorylation in contracted muscle from skeletal muscle-specific AMPK β 1 β 2 KO mice concomitantly with decreased glucose transport (O'Neill et al. 2011).

3- Genetically modified fly models

AMPK system is highly conserved between insects and mammals. *Drosophila* AMPK contains three protein subunits, α , β and γ , which are encoded, in contrast to mammalian

AMPK, by single genes named dAMPK α , alicorn and loechrig (also known as SNF4A γ), respectively (Pan and Hardie 2002) (**Figure 2**), making *Drosophila* an attractive animal model to study AMPK functions *in vivo*. However, *Drosophila* expresses several isoforms for each subunit generated from alternative splicing and differential transcription initiation (Tschape et al. 2002) and can presumably form a high number of different heterotrimeric complexes. Like mammalian AMPK, drosophila AMPK is allosterically activated by AMP and by treatments that depleted cellular ATP. This is associated with phosphorylation of Thr-184 within the activation loop of dAMPK α and of acetyl-CoA carboxylase at a homologous site also conserved between mammals and insects (Pan and Hardie 2002). Although mice have been the most commonly used animal model to decipher the biology of AMPK, genetically engineered fruit fly *Drosophila melanogaster* (**Tables 3 and 4**) has been particularly important in demonstrating the role of AMPK in the regulation of cell polarity during energy stress and in neuronal survival (Tschape et al. 2002, Lee et al. 2007, Mirouse et al. 2007, Spasic et al. 2008). Identification and generation of mutant AMPK drosophila has been realized by forward genetic screens using ethylmethanesulfonate (EMS) mutagenesis (Medina et al. 2006) or by the P-element transposon technology (Rubin and Spradling 1982). Germline transformation of drosophila can be realized via insertion of a single P transposable element or by imprecise mobilization of the P-elements (excision) to generate null mutants. In addition, creation of transgenic flies using different approaches, including the UAS/Gal4 and "tet-on" systems (Tower 2000), have been instrumental to complement more traditional genetics.

The *Drosophila loechrig* (*loe*) mutant is characterized by degeneration and severe vacuolization (*loechrig* is the German word for full of holes) in the brain. The mutation in *loe* is caused by the insertion of a P-element that affects a neuronal isoform of the AMPK γ subunit (Tschape et al. 2002). Interestingly, among the six different *Drosophila* AMPK γ isoforms, this particular protein isoform strongly expressed in the nervous system contains a unique N-terminus and is the only isoform to rescue the *loe* phenotype when expressed in neurons, highlighting its specific role for the integrity of the central nervous system. The *loe/AMPK γ* mutation affects the regulatory function of AMPK on isoprenoid synthesis via the inhibition of its downstream target hydroxymethylglutaryl (HMG)-CoA reductase and that changes play a pivotal role in the observed degenerative phenotype (Tschape et al. 2002). The loss of functional neuronal

AMPK upregulates the synthesis of isoprenoids leading to increased prenylation of the small GTPase Rho1, the fly ortholog of vertebrate RhoA, and thereby progressive neurodegeneration (Cook et al. 2012). Upregulation of RhoA signaling pathway induces changes in the actin cytoskeleton through an increase in phosphorylated cofilin and accumulation of F-actin, resulting in deleterious consequences on neuronal growth and impaired axonal integrity (Cook et al. 2014). Additional evidence for a role of AMPK in neuroprotective processes comes from the study of a P-element insertion line found to target *alicorn* (*alc*), encoding the *Drosophila* homolog of the regulatory AMPK β subunit. Disruption of the *alc*/AMPK β gene causes early-onset progressive retinal degeneration, characterized by extensive vacuolization and general structural disorganization (Spasic et al. 2008). The mechanism of progressive neuronal death observed as a consequence of loss of AMPK does not involve apoptosis (Tschape et al. 2002, Poels et al. 2012). It has been suggested that AMPK could contribute to the protection of neurons from increased metabolic activity by the regulation of the autophagic process. Accordingly, the *loechrig/SNF4A γ* gene has been identified in a genetic screen to select P-element insertion that affect autophagy in the larval fat body (Lippai et al. 2008). Surprisingly, in *alc* mutants, a severe induction of autophagy was reported (Poels et al. 2012). This is most likely a consequence of the absence of the negative regulatory feedback loop mediated by AMPK in condition of excessive autophagic induction (Loffler et al. 2011).

Parkinson's disease is one of the most common neurodegenerative diseases in the aging population. Recently, a *Drosophila* Parkinson's disease model was used as an initial system to evaluate the therapeutic potential of a number of candidate compounds (Ng et al. 2012). Epigallocatechin gallate (EGCG), a green tea-derived catechin, was found to provide the best protection against the loss of dopaminergic neurons and mitochondrial dysfunction, the essential pathological phenotypes of human Parkinson's patients. Importantly, the protective effects of EGCG are abolished when AMPK is knocked down, and loss of AMPK activity exacerbates neuronal loss and associated phenotypes (Ng et al. 2012), suggestive of a pathological role of AMPK in neurodegenerative diseases. In addition, it was demonstrated that genetic activation of AMPK also protects against neuronal loss and reproduces EGCG's protective effects, indicating that targeting AMPK will be useful therapeutically in the treatment of neurodegenerative disorders. Indeed, as mitochondrial dysfunction is currently widely accepted to be a key driver of neurodegeneration, activation of AMPK could preserve neuronal function by preserving

the energy balance and by restoring the clearance of damaged mitochondria via induction of mitophagy through the phosphorylation of the autophagy initiator autophagy-related gene 1 (Atg1)/ Unc-51-like kinase 1 (ULK1).

In agreement, with a role of AMPK in neural maintenance, lethal mutations in AMPK α , identified by forward genetic screen with EMS mutagenesis or generated by imprecise excision of P-elements, confirmed the importance for the kinase in the maintenance of cell integrity (Lee et al. 2007, Swick et al. 2013). AMPK α -null fly embryos showed severe abnormalities in cell polarity and disorganization of epithelial structures and lead to embryonic lethality (Lee et al. 2007). Moreover, AMPK-null embryos contained defective mitotic divisions with lagging or polyploid chromosomes. It was established that AMPK functions in mitosis and epithelial polarity by targeting myosin II regulatory light chain (MRLC), since phosphomimetic mutant of MRLC rescued the AMPK-null defects in cell polarity and mitosis (Lee et al. 2007). These findings uncovered a link between energy status and cell structures, revealing new pathophysiological functions for AMPK signaling pathway in the regulation of cellular structures.

Drosophila has been used as a model system to dissect possible roles of AMPK in aging and lifespan determination. Dietary restriction, a reduction in total food intake, has been shown to increase lifespan by modulating nutrient-sensing pathways in flies as well as in a wide range of organisms including nematodes and mammals (Fontana et al. 2010). However, question remains regarding the importance of cellular energy homeostasis and AMPK signaling as an evolutionary conserved determinant of life span control. For this purpose, to circumvent the lethality caused by AMPK α deletion in late larval stages (Lee et al. 2007), the consequences of tissue-specific knock-down of AMPK α and transgenic expression of AMPK α using the inducible GeneSwitch system (Poirier et al. 2008), which provided both temporal and spatial control, have been examined to influence *drosophila* life span. Different approaches were used including RNAi-mediated knock-down of AMPK α (Tohyama and Yamaguchi 2010) or AMPK γ (Johnson et al. 2010) and expression of a dominant negative construct (AMPK α^{K57A}), in which the catalytic domain of the AMPK α subunit is inactive (Johnson et al. 2010) (**Table 4**). Consistent with a causal role for AMPK in regulating energy homeostasis, reduced AMPK signaling leads to hypersensitivity to starvation conditions (Bland et al. 2010, Johnson et al. 2010, Tohyama and Yamaguchi 2010). Interestingly, a similar sensitivity to starvation conditions was observed with a selective loss of AMPK signaling in muscle (Tohyama

and Yamaguchi 2010) and was associated with a reduction in lifespan (Bland et al. 2010, Stenesen et al. 2013), suggesting potential tissue-specific requirements for AMPK-mediated lifespan extension. To study the impact of tissue-restricted upregulation of AMPK, pro-longevity effects were investigated in transgenic flies overexpressing AMPK in a subset of metabolic tissues. It was found that localized AMPK activation (e.g., by overexpressing wild-type AMPK in muscle, fat body, brain or intestinal epithelium) extends lifespan a non-cell-autonomous manner (Bland et al. 2010, Stenesen et al. 2013, Ulgherait et al. 2014). Activation of AMPK produces a non-cell autonomous induction of autophagy due to upregulation of Atg1/ULK1 signaling, which appears to be necessary and sufficient to slows systemic aging (Ulgherait et al. 2014). A recent study demonstrated that dietary application of β -guanidinopropionic acid (β -GPA), a creatine analog, can extend lifespan through AMPK-dependent induction of autophagy (Yang et al. 2015). Such findings may provide significant insight for pharmaceutical strategies to manipulate AMPK function in single tissue to prolong lifespan in mammals.

4- Genetically modified worm models

The nematode *Caenorhabditis elegans* has many excellent advantages as an *in vivo* model for detailed molecular analyses and functional genomics. It is a small nematode with a life cycle of 3.5 days and a lifespan of about 2-3 weeks. In addition, *C. elegans* displays conserved developmental programs, genetic tractability, and a fully sequenced genome, making an ideal model system to understand biological processes. To identify the biological function of specific genes in *C. elegans*, different methods have been developed using reverse and forward genetics or transgenesis techniques (Baylis and Vazquez-Manrique 2011, Boulin and Hobert 2012). *C. elegans* has many genes which are similar to those of other higher eukaryotes, suggesting many similar functions in cellular and molecular mechanisms. The *C. elegans* genome encodes the *aak-1* and *aak-2* genes, which are homologs of the catalytic α subunits of mammalian AMPK, the *aakb-1* and *aakb-2* genes, which are homologs of the regulatory β subunits of mammalian AMPK, and the *aakg-1*, *aakg-2*, *aakg-3*, *aakg-4* and *aakg-5* genes, which are homologs of the regulatory γ subunits of mammalian AMPK (Apfeld et al. 2004) (**Figure 2**). Hence, a potential of 20 alternative heterotrimeric complexes can be formed in *C. elegans*.

During the last decade, *C. elegans* has been at the forefront as a model system to understand biological processes linking energetics to longevity. Limiting energy

availability through dietary restriction confers lifespan extension in organisms as diverse as yeasts, nematodes, and rodents (Fontana et al. 2010). It has been found that increases in cellular AMP/ATP ratio are associated with age in *C. elegans*, suggesting a link between genes known to affect lifespan and the control of energy metabolism (Apfeld et al. 2004). Thus, it is not surprising that AMPK has emerged as a key regulator of lifespan determination (Burkewitz et al. 2014). The use of *aak-2* mutants (**Table 5**) has highlighted the role of AMPK in the regulation of lifespan in response to environmental stress and insulin-like signaling (Apfeld et al. 2004, Narbonne and Roy 2006). *C. elegans* lacking *aak-2* failed to extend lifespan in response dietary restriction and low energy conditions (Greer et al. 2007, Schulz et al. 2007, Lee et al. 2008, Narbonne and Roy 2009, Fukuyama et al. 2012). Conversely, overexpression of *aak-2* significantly promotes lifespan extension and mimics dietary restriction in well-fed wild-type animals (Apfeld et al. 2004). Similar increase in lifespan is observed in transgenic worms expressing an active form of the AMPK α (Mair et al. 2011) or the AMPK γ (Greer et al. 2007) subunits. *C. elegans* fed with the AMPK agonist metformin also display increase in lifespan that is dependent on *aak-2* (Onken and Driscoll 2010). The effect of metformin on extension of *C. elegans* lifespan can be direct by promoting resistance to biguanide toxicity through AMPK activation and indirect by impairing folate metabolism of *E. coli*, its trophic microbial partner (Cabreiro et al. 2013).

Under condition of energetic stress, the *aak-2* subunit becomes phosphorylated at threonine 243 (Thr243), equivalent to Thr172 in the mammalian ortholog, and primarily takes part in its activity to phosphorylate and inhibits the CREB-regulated transcriptional coactivator CRTC-1, a cofactor involved in diverse physiological processes including energy homeostasis (Mair et al. 2011). Modulation of CRTC-1 phosphorylation status by AMPK activation in the central nervous system is required to locally and cell autonomously promote remodeling of mitochondrial metabolic networks and increase longevity (Burkewitz et al. 2015). Upon reduced AMPK activity, CRTC-1 modulates AMPK-mediated longevity cell nonautonomously via regulation of the neurotransmitter/hormone octopamine secretion, which drives mitochondrial fragmentation in distal tissues, and suppresses the effects of AMPK on systemic mitochondrial metabolism and longevity. These findings highlight the dominance of neuronal energy-sensing mechanisms and neuronal signals on systemic metabolic homeostasis and impact on aging process. This regulatory mechanism is consistent with

the cell-nonautonomous role for neuronal AMPK in modulating peripheral lipid storage in worms (Cunningham et al. 2014).

Concluding remarks

The AMP-activated protein kinase (AMPK) system was first discovered 35 years ago. Since that time, knowledge of the diverse physiological functions of AMPK has grown rapidly and continues to evolve. Most certainly, genetically modified mice have become instrumental to the study of AMPK. However, the use of fly and worm model organisms has also played a key role in delineating the physiological role of AMPK signaling pathway and will continue to contribute to the expanding field of AMPK.

Identifying the best animal model to study AMPK function or characterize AMPK agonists/ antagonists is an important consideration and requires a thorough understanding of the advantages and disadvantages of each animal model, as there are important factors to consider. Animal models with comparable AMPK heterotrimeric composition to human cells and tissues are typically relevant models to examine AMPK pathophysiological role and develop tissue-specific therapeutic interventions. However, although mouse models possess many advantages for biomedical research, it has been reported that the composition of AMPK heterotrimers differ between rodent and human hepatocytes (Stephene et al. 2011, Wu et al. 2013), addressing a major challenge for future pre-clinical translational studies.

References

- Ahmad, F., M. Arad, N. Musi, H. He, C. Wolf, D. Branco, A. R. Perez-Atayde, D. Stapleton, D. Bali, Y. Xing, R. Tian, L. J. Goodyear, C. I. Berul, J. S. Ingwall, C. E. Seidman and J. G. Seidman (2005). "Increased alpha2 subunit-associated AMPK activity and PRKAG2 cardiomyopathy." *Circulation* **112**(20): 3140-3148.
- Akman, H. O., J. N. Sampayo, F. A. Ross, J. W. Scott, G. Wilson, L. Benson, C. Bruno, S. Shanske, D. G. Hardie and S. Dimauro (2007). "Fatal infantile cardiac glycogenosis with phosphorylase kinase deficiency and a mutation in the gamma2-subunit of AMP-activated protein kinase." *Pediatr Res* **62**(4): 499-504.
- Andreelli, F., M. Foretz, C. Knauf, P. D. Cani, C. Perrin, M. A. Iglesias, B. Pillot, A. Bado, F. Tronche, G. Mithieux, S. Vaulont, R. Burcelin and B. Viollet (2006). "Liver adenosine monophosphate-activated kinase-alpha2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin." *Endocrinology* **147**(5): 2432-2441.
- Apfeld, J., G. O'Connor, T. McDonagh, P. S. DiStefano and R. Curtis (2004). "The AMP-activated protein kinase AAK-2 links energy levels and insulin-like signals to lifespan in *C. elegans*." *Genes & development* **18**(24): 3004-3009.
- Arad, M., D. W. Benson, A. R. Perez-Atayde, W. J. McKenna, E. A. Sparks, R. J. Kanter, K. McGarry, J. G. Seidman and C. E. Seidman (2002). "Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy." *The Journal of clinical investigation* **109**(3): 357-362.
- Arad, M., B. J. Maron, J. M. Gorham, W. H. Johnson, Jr., J. P. Saul, A. R. Perez-Atayde, P. Spirito, G. B. Wright, R. J. Kanter, C. E. Seidman and J. G. Seidman (2005). "Glycogen storage diseases presenting as hypertrophic cardiomyopathy." *N Engl J Med* **352**(4): 362-372.
- Arad, M., I. P. Moskowitz, V. V. Patel, F. Ahmad, A. R. Perez-Atayde, D. B. Sawyer, M. Walter, G. H. Li, P. G. Burgon, C. T. Maguire, D. Stapleton, J. P. Schmitt, X. X. Guo, A. Pizard, S. Kupersmidt, D. M. Roden, C. I. Berul, C. E. Seidman and J. G. Seidman (2003).

"Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy." Circulation **107**(22): 2850-2856.

Banerjee, S. K., K. R. McGaffin, X. N. Huang and F. Ahmad (2010). "Activation of cardiac hypertrophic signaling pathways in a transgenic mouse with the human PRKAG2 Thr400Asn mutation." Biochim Biophys Acta **1802**(2): 284-291.

Banerjee, S. K., R. Ramani, S. Saba, J. Rager, R. Tian, M. A. Mathier and F. Ahmad (2007). "A PRKAG2 mutation causes biphasic changes in myocardial AMPK activity and does not protect against ischemia." Biochemical and biophysical research communications **360**(2): 381-387.

Banerjee, S. K., D. W. Wang, R. Alzamora, X. N. Huang, N. M. Pastor-Soler, K. R. Hallows, K. R. McGaffin and F. Ahmad (2010). "SGLT1, a novel cardiac glucose transporter, mediates increased glucose uptake in PRKAG2 cardiomyopathy." J Mol Cell Cardiol **49**(4): 683-692.

Barnes, B. R., Y. C. Long, T. L. Steiler, Y. Leng, D. Galuska, J. F. Wojtaszewski, L. Andersson and J. R. Zierath (2005). "Changes in exercise-induced gene expression in 5'-AMP-activated protein kinase gamma3-null and gamma3 R225Q transgenic mice." Diabetes **54**(12): 3484-3489.

Barnes, B. R., S. Marklund, T. L. Steiler, M. Walter, G. Hjalms, V. Amarger, M. Mahlapuu, Y. Leng, C. Johansson, D. Galuska, K. Lindgren, M. Abrink, D. Stapleton, J. R. Zierath and L. Andersson (2004). "The 5'-AMP-activated protein kinase gamma3 isoform has a key role in carbohydrate and lipid metabolism in glycolytic skeletal muscle." The Journal of biological chemistry **279**(37): 38441-38447.

Barre, L., C. Richardson, M. F. Hirshman, J. Brozinick, S. Fiering, B. E. Kemp, L. J. Goodyear and L. A. Witters (2007). "Genetic model for the chronic activation of skeletal muscle AMP-activated protein kinase leads to glycogen accumulation." American journal of physiology **292**(3): E802-811.

Baylis, H. A. and R. P. Vazquez-Manrique (2011). "Reverse genetic strategies in *Caenorhabditis elegans*: towards controlled manipulation of the genome." ScientificWorldJournal **11**: 1394-1410.

Bayrak, F., E. Komurcu-Bayrak, B. Mutlu, G. Kahveci, Y. Basaran and N. Erginel-Unaltuna (2006). "Ventricular pre-excitation and cardiac hypertrophy mimicking hypertrophic

cardiomyopathy in a Turkish family with a novel PRKAG2 mutation." Eur J Heart Fail **8**(7): 712-715.

Blagih, J., F. Coulombe, E. E. Vincent, F. Dupuy, G. Galicia-Vazquez, E. Yurchenko, T. C. Raissi, G. J. van der Windt, B. Viollet, E. L. Pearce, J. Pelletier, C. A. Piccirillo, C. M. Krawczyk, M. Divangahi and R. G. Jones (2015). "The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo." Immunity **42**(1): 41-54.

Blair, E., C. Redwood, H. Ashrafian, M. Oliveira, J. Broxholme, B. Kerr, A. Salmon, I. Ostman-Smith and H. Watkins (2001). "Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis." Human molecular genetics **10**(11): 1215-1220.

Bland, M. L., R. J. Lee, J. M. Magallanes, J. K. Foskett and M. J. Birnbaum (2010). "AMPK supports growth in Drosophila by regulating muscle activity and nutrient uptake in the gut." Dev Biol **344**(1): 293-303.

Boulin, T. and O. Hobert (2012). "From genes to function: the C. elegans genetic toolbox." Wiley Interdiscip Rev Dev Biol **1**(1): 114-137.

Buhl, E. S., N. Jessen, R. Pold, T. Ledet, A. Flyvbjerg, S. B. Pedersen, O. Pedersen, O. Schmitz and S. Lund (2002). "Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome." Diabetes **51**(7): 2199-2206.

Burkewitz, K., I. Morantte, H. J. Weir, R. Yeo, Y. Zhang, F. K. Huynh, O. R. Ilkayeva, M. D. Hirschey, A. R. Grant and W. B. Mair (2015). "Neuronal CRTCL1 governs systemic mitochondrial metabolism and lifespan via a catecholamine signal." Cell **160**(5): 842-855.

Burkewitz, K., Y. Zhang and W. B. Mair (2014). "AMPK at the nexus of energetics and aging." Cell Metab **20**(1): 10-25.

Burwinkel, B., J. W. Scott, C. Buhner, F. K. van Landeghem, G. F. Cox, C. J. Wilson, D. Grahame Hardie and M. W. Kilimann (2005). "Fatal congenital heart glycogenesis caused by a recurrent activating R531Q mutation in the gamma 2-subunit of AMP-activated protein kinase (PRKAG2), not by phosphorylase kinase deficiency." Am J Hum Genet **76**(6): 1034-1049.

Cabreiro, F., C. Au, K. Y. Leung, N. Vergara-Irigaray, H. M. Cocheme, T. Noori, D. Weinkove, E. Schuster, N. D. Greene and D. Gems (2013). "Metformin retards aging in *C. elegans* by altering microbial folate and methionine metabolism." Cell **153**(1): 228-239.

Chen, Z. P., G. K. McConell, B. J. Michell, R. J. Snow, B. J. Canny and B. E. Kemp (2000). "AMPK signaling in contracting human skeletal muscle: acetyl-CoA carboxylase and NO synthase phosphorylation." American journal of physiology. Endocrinology and metabolism **279**(5): E1202-1206.

Cheung, P. C., I. P. Salt, S. P. Davies, D. G. Hardie and D. Carling (2000). "Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding." Biochem J **346 Pt 3**: 659-669.

Ciobanu, D., J. Bastiaansen, M. Malek, J. Helm, J. Woollard, G. Plastow and M. Rothschild (2001). "Evidence for new alleles in the protein kinase adenosine monophosphate-activated gamma(3)-subunit gene associated with low glycogen content in pig skeletal muscle and improved meat quality." Genetics **159**(3): 1151-1162.

Claret, M., M. A. Smith, R. L. Batterham, C. Selman, A. I. Choudhury, L. G. Fryer, M. Clements, H. Al-Qassab, H. Heffron, A. W. Xu, J. R. Speakman, G. S. Barsh, B. Viollet, S. Vaulont, M. L. Ashford, D. Carling and D. J. Withers (2007). "AMPK is essential for energy homeostasis regulation and glucose-sensing by POMC and AgRP neurons " J Clin Invest **117**(8): 2325-2336.

Cook, M., B. J. Bolkan and D. Kretschmar (2014). "Increased actin polymerization and stabilization interferes with neuronal function and survival in the AMPKgamma mutant Loechrig." PLoS One **9**(2): e89847.

Cook, M., P. Mani, J. S. Wentzell and D. Kretschmar (2012). "Increased RhoA prenylation in the loe chrig (loe) mutant leads to progressive neurodegeneration." PLoS One **7**(9): e44440.

Cool, B., B. Zinker, W. Chiou, L. Kifle, N. Cao, M. Perham, R. Dickinson, A. Adler, G. Gagne, R. Iyengar, G. Zhao, K. Marsh, P. Kym, P. Jung, H. S. Camp and E. Frevert (2006). "Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome." Cell Metab **3**(6): 403-416.

Costford, S. R., N. Kavaslar, N. Ahituv, S. N. Chaudhry, W. S. Schackwitz, R. Dent, L. A. Pennacchio, R. McPherson and M. E. Harper (2007). "Gain-of-function R225W mutation in human AMPKgamma(3) causing increased glycogen and decreased triglyceride in skeletal muscle." PLoS One **2**(9): e903.

Cunningham, K. A., A. D. Bouagnon, A. G. Barros, L. Lin, L. Malard, M. A. Romano-Silva and K. Ashrafi (2014). "Loss of a neural AMP-activated kinase mimics the effects of elevated serotonin on fat, movement, and hormonal secretions." PLoS genetics **10**(6): e1004394.

Daniel, T. and D. Carling (2002). "Functional analysis of mutations in the gamma 2 subunit of AMP-activated protein kinase associated with cardiac hypertrophy and Wolff-Parkinson-White syndrome." J Biol Chem **277**(52): 51017-51024.

Dasgupta, B., J. S. Ju, Y. Sasaki, X. Liu, S. R. Jung, K. Higashida, D. Lindquist and J. Milbrandt (2012). "The AMPK beta2 subunit is required for energy homeostasis during metabolic stress." Mol Cell Biol **32**(14): 2837-2848.

Dasgupta, B. and J. Milbrandt (2009). "AMP-activated protein kinase phosphorylates retinoblastoma protein to control mammalian brain development." Dev Cell **16**(2): 256-270.

Davies, J. K., D. J. Wells, K. Liu, H. R. Whitrow, T. D. Daniel, R. Grignani, C. A. Lygate, J. E. Schneider, G. Noel, H. Watkins and D. Carling (2006). "Characterization of the role of gamma2 R531G mutation in AMP-activated protein kinase in cardiac hypertrophy and Wolff-Parkinson-White syndrome." American journal of physiology **290**(5): H1942-1951.

Deak, P., M. M. Omar, R. D. Saunders, M. Pal, O. Komonyi, J. Szidonya, P. Maroy, Y. Zhang, M. Ashburner, P. Benos, C. Savakis, I. Siden-Kiamos, C. Louis, V. N. Bolshakov, F. C. Kafatos, E. Madueno, J. Modolell and D. M. Glover (1997). "P-element insertion alleles of essential genes on the third chromosome of *Drosophila melanogaster*: correlation of physical and cytogenetic maps in chromosomal region 86E-87F." Genetics **147**(4): 1697-1722.

Dietzl, G., D. Chen, F. Schnorrer, K. C. Su, Y. Barinova, M. Fellner, B. Gasser, K. Kinsey, S. Oettel, S. Scheiblauer, A. Couto, V. Marra, K. Keleman and B. J. Dickson (2007). "A genome-wide transgenic RNAi library for conditional gene inactivation in *Drosophila*." Nature **448**(7150): 151-156.

Dockendorff, T. C., S. E. Robertson, D. L. Faulkner and T. A. Jongens (2000). "Genetic characterization of the 44D-45B region of the *Drosophila melanogaster* genome based on an F2 lethal screen." Mol Gen Genet **263**(1): 137-143.

Dzamko, N., B. J. van Denderen, A. L. Hevener, S. B. Jorgensen, J. Honeyman, S. Galic, Z. P. Chen, M. J. Watt, D. J. Campbell, G. R. Steinberg and B. E. Kemp (2010). "AMPK beta1 deletion reduces appetite, preventing obesity and hepatic insulin resistance." The Journal of biological chemistry **285**(1): 115-122.

Enfalt, A. C., K. Lundstrom, A. Karlsson and I. Hansson (1997). "Estimated frequency of the RN- allele in Swedish Hampshire pigs and comparison of glycolytic potential, carcass composition, and technological meat quality among Swedish Hampshire, Landrace, and Yorkshire pigs." Journal of animal science **75**(11): 2924-2935.

Essen-Gustavsson, B., A. Granlund, B. Benziene, M. Jensen-Waern and A. V. Chibalin (2011). "Muscle glycogen resynthesis, signalling and metabolic responses following acute exercise in exercise-trained pigs carrying the PRKAG3 mutation." Exp Physiol **96**(9): 927-937.

Estrade, M., S. Ayoub, A. Talmant and G. Monin (1994). "Enzyme activities of glycogen metabolism and mitochondrial characteristics in muscles of RN- carrier pigs (*Sus scrofa domestica*)." Comparative biochemistry and physiology. Biochemistry and molecular biology **108**(3): 295-301.

Folmes, K. D., A. Y. Chan, D. P. Koonen, T. C. Pulinilkunnil, I. Baczko, B. E. Hunter, S. Thorn, M. F. Allard, R. Roberts, M. H. Gollob, P. E. Light and J. R. Dyck (2009). "Distinct early signaling events resulting from the expression of the PRKAG2 R302Q mutant of AMPK contribute to increased myocardial glycogen." Circ Cardiovasc Genet **2**(5): 457-466.

Fontana, L., L. Partridge and V. D. Longo (2010). "Extending healthy life span--from yeast to humans." Science **328**(5976): 321-326.

Foretz, M., S. Guihard, J. Leclerc, V. Fauveau, J. P. Couty, F. Andris, M. Gaudry, F. Andreelli, S. Vaulont and B. Viollet (2010). "Maintenance of red blood cell integrity by AMP-activated protein kinase alpha1 catalytic subunit." FEBS Lett **584**(16): 3667-3671.

Foretz, M., S. Hebrard, S. Guihard, J. Leclerc, M. Do Cruzeiro, G. Hamard, F. Niedergang, M. Gaudry and B. Viollet (2011). "The AMPKgamma1 subunit plays an essential role in

erythrocyte membrane elasticity, and its genetic inactivation induces splenomegaly and anemia." FASEB J **25**(1): 337-347.

Fu, X., J. X. Zhao, M. J. Zhu, M. Foretz, B. Viollet, M. V. Dodson and M. Du (2013). "AMP-activated protein kinase alpha1 but not alpha2 catalytic subunit potentiates myogenin expression and myogenesis." Mol Cell Biol **33**(22): 4517-4525.

Fu, X., M. Zhu, S. Zhang, M. Foretz, B. Viollet and M. Du (2016). "Obesity Impairs Skeletal Muscle Regeneration Through Inhibition of AMPK." Diabetes **65**(1): 188-200.

Fu, X., M. J. Zhu, M. V. Dodson and M. Du (2015). "AMP-activated protein kinase stimulates Warburg-like glycolysis and activation of satellite cells during muscle regeneration." J Biol Chem **290**(44): 26445-26456.

Fujii, N., T. Hayashi, M. F. Hirshman, J. T. Smith, S. A. Habinowski, L. Kaijser, J. Mu, O. Ljungqvist, M. J. Birnbaum, L. A. Witters, A. Thorell and L. J. Goodyear (2000). "Exercise induces isoform-specific increase in 5'AMP-activated protein kinase activity in human skeletal muscle." Biochemical and biophysical research communications **273**(3): 1150-1155.

Fujii, N., M. F. Hirshman, E. M. Kane, R. C. Ho, L. E. Peter, M. M. Seifert and L. J. Goodyear (2005). "AMP-activated protein kinase alpha2 activity is not essential for contraction- and hyperosmolarity-induced glucose transport in skeletal muscle." The Journal of biological chemistry **280**(47): 39033-39041.

Fujii, N., M. M. Seifert, E. M. Kane, L. E. Peter, R. C. Ho, S. Winstead, M. F. Hirshman and L. J. Goodyear (2007). "Role of AMP-activated protein kinase in exercise capacity, whole body glucose homeostasis, and glucose transport in skeletal muscle -insight from analysis of a transgenic mouse model." Diabetes Res Clin Pract **77 Suppl 1**: S92-98.

Fukuyama, M., K. Sakuma, R. Park, H. Kasuga, R. Nagaya, Y. Atsumi, Y. Shimomura, S. Takahashi, H. Kajiho, A. Rougvie, K. Kontani and T. Katada (2012). "C. elegans AMPKs promote survival and arrest germline development during nutrient stress." Biol Open **1**(10): 929-936.

Fullerton, M. D., S. Galic, K. Marcinko, S. Sikkema, T. Pulinilkunnil, Z. P. Chen, H. M. O'Neill, R. J. Ford, R. Palanivel, M. O'Brien, D. G. Hardie, S. L. Macaulay, J. D. Schertzer, J. R. Dyck, B. J. van Denderen, B. E. Kemp and G. R. Steinberg (2013). "Single phosphorylation

sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin." Nat Med **19**(12): 1649-1654.

Galic, S., M. D. Fullerton, J. D. Schertzer, S. Sikkema, K. Marcinko, C. R. Walkley, D. Izon, J. Honeyman, Z. P. Chen, B. J. van Denderen, B. E. Kemp and G. R. Steinberg (2011). "Hematopoietic AMPK beta1 reduces mouse adipose tissue macrophage inflammation and insulin resistance in obesity." J Clin Invest **121**(12): 4903-4915.

Garcia-Roves, P. M., M. E. Osler, M. H. Holmstrom and J. R. Zierath (2008). "Gain-of-function R225Q mutation in AMP-activated protein kinase gamma3 subunit increases mitochondrial biogenesis in glycolytic skeletal muscle." J Biol Chem **283**(51): 35724-35734.

Gollob, M. H., M. S. Green, A. S. Tang, T. Gollob, A. Karibe, A. S. Ali Hassan, F. Ahmad, R. Lozado, G. Shah, L. Fananapazir, L. L. Bachinski and R. Roberts (2001). "Identification of a gene responsible for familial Wolff-Parkinson-White syndrome." The New England journal of medicine **344**(24): 1823-1831.

Gollob, M. H., J. J. Seger, T. N. Gollob, T. Tapscott, O. Gonzales, L. Bachinski and R. Roberts (2001). "Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction system disease with childhood onset and absence of cardiac hypertrophy." Circulation **104**(25): 3030-3033.

Gong, H., J. Xie, N. Zhang, L. Yao and Y. Zhang (2011). "MEF2A binding to the Glut4 promoter occurs via an AMPKalpha2-dependent mechanism." Med Sci Sports Exerc **43**(8): 1441-1450.

Granlund, A., M. Jensen-Waern and B. Essen-Gustavsson (2011). "The influence of the PRKAG3 mutation on glycogen, enzyme activities and fibre types in different skeletal muscles of exercise trained pigs." Acta Vet Scand **53**: 20.

Granlund, A., O. Kotova, B. Benziane, D. Galuska, M. Jensen-Waern, A. V. Chibalin and B. Essen-Gustavsson (2010). "Effects of exercise on muscle glycogen synthesis signalling and enzyme activities in pigs carrying the PRKAG3 mutation." Exp Physiol **95**(4): 541-549.

Greer, E. L., D. Dowlatshahi, M. R. Banko, J. Villen, K. Hoang, D. Blanchard, S. P. Gygi and A. Brunet (2007). "An AMPK-FOXO pathway mediates longevity induced by a novel method of dietary restriction in *C. elegans*." Current biology : CB **17**(19): 1646-1656.

Guigas, B., L. Bertrand, N. Taleux, M. Foretz, N. Wiernsperger, D. Vertommen, F. Andreelli, B. Viollet and L. Hue (2006). "5-Aminoimidazole-4-Carboxamide-1- β -D-Ribofuranoside and Metformin Inhibit Hepatic Glucose Phosphorylation by an AMP-Activated Protein Kinase-Independent Effect on Glucokinase Translocation." Diabetes **55**(4): 865-874.

Gundewar, S., J. W. Calvert, S. Jha, I. Toedt-Pingel, S. Y. Ji, D. Nunez, A. Ramachandran, M. Anaya-Cisneros, R. Tian and D. J. Lefer (2009). "Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure." Circ Res **104**(3): 403-411.

Halseth, A. E., N. J. Ensor, T. A. White, S. A. Ross and E. A. Gulve (2002). "Acute and chronic treatment of ob/ob and db/db mice with AICAR decreases blood glucose concentrations." Biochem Biophys Res Commun **294**(4): 798-805.

Hamilton, S. R., D. Stapleton, J. B. O'Donnell, J. T. Kung, S. R. Dalal, B. E. Kemp and L. A. Witters (2001). "An activating mutation in the gamma1 subunit of the AMP-activated protein kinase." FEBS Lett **500**(3): 163-168.

Hardie, D. G. (2014). "AMP-activated protein kinase: maintaining energy homeostasis at the cellular and whole-body levels." Annu Rev Nutr **34**: 31-55.

Hedegaard, J., P. Horn, R. Lametsch, H. Sondergaard Moller, P. Roepstorff, C. Bendixen and E. Bendixen (2004). "UDP-glucose pyrophosphorylase is upregulated in carriers of the porcine RN- mutation in the AMP-activated protein kinase." Proteomics **4**(8): 2448-2454.

Huang, L. S., J. W. Ma, J. Ren, N. S. Ding, Y. M. Guo, H. S. Ai, L. Li, L. H. Zhou and C. Y. Chen (2004). "Genetic variations of the porcine PRKAG3 gene in Chinese indigenous pig breeds." Genet Sel Evol **36**(4): 481-486.

Hue, L. and H. Taegtmeyer (2009). "The Randle cycle revisited: a new head for an old hat." Am J Physiol Endocrinol Metab **297**(3): E578-591.

Jansen, G., E. Hazendonk, K. L. Thijssen and R. H. Plasterk (1997). "Reverse genetics by chemical mutagenesis in *Caenorhabditis elegans*." Nature genetics **17**(1): 119-121.

Johnson, E. C., N. Kazgan, C. A. Bretz, L. J. Forsberg, C. E. Hector, R. J. Worthen, R. Onyenwoke and J. E. Brenman (2010). "Altered metabolism and persistent starvation behaviors caused by reduced AMPK function in *Drosophila*." *PLoS One* **5**(9).

Jorgensen, S. B., J. N. Nielsen, J. B. Birk, G. S. Olsen, B. Viollet, F. Andreelli, P. Schjerling, S. Vaulont, D. G. Hardie, B. F. Hansen, E. A. Richter and J. F. Wojtaszewski (2004). "The alpha2-5'AMP-activated protein kinase is a site 2 glycogen synthase kinase in skeletal muscle and is responsive to glucose loading." *Diabetes* **53**(12): 3074-3081.

Jorgensen, S. B., B. Viollet, F. Andreelli, C. Frosig, J. B. Birk, P. Schjerling, S. Vaulont, E. A. Richter and J. F. Wojtaszewski (2004). "Knockout of the alpha2 but not alpha1 5'-AMP-activated protein kinase isoform abolishes 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranosidebut not contraction-induced glucose uptake in skeletal muscle." *J Biol Chem* **279**(2): 1070-1079.

Kazgan, N., T. Williams, L. J. Forsberg and J. E. Brenman (2010). "Identification of a nuclear export signal in the catalytic subunit of AMP-activated protein kinase." *Mol Biol Cell* **21**(19): 3433-3442.

Kelly, B. P., M. W. Russell, J. R. Hennessy and G. J. Ensing (2009). "Severe hypertrophic cardiomyopathy in an infant with a novel PRKAG2 gene mutation: potential differences between infantile and adult onset presentation." *Pediatr Cardiol* **30**(8): 1176-1179.

Kim, M., R. W. Hunter, L. Garcia-Menendez, G. Gong, Y. Y. Yang, S. C. Kolwicz, Jr., J. Xu, K. Sakamoto, W. Wang and R. Tian (2014). "Mutation in the gamma2-subunit of AMP-activated protein kinase stimulates cardiomyocyte proliferation and hypertrophy independent of glycogen storage." *Circ Res* **114**(6): 966-975.

Kohlstedt, K., C. Trouvain, T. Boettger, L. Shi, B. Fisslthaler and I. Fleming (2013). "AMP-activated protein kinase regulates endothelial cell angiotensin-converting enzyme expression via p53 and the post-transcriptional regulation of microRNA-143/145." *Circ Res* **112**(8): 1150-1158.

Kone, M., T. J. Pullen, G. Sun, M. Ibberson, A. Martinez-Sanchez, S. Sayers, M. S. Nguyen-Tu, C. Kantor, A. Swisa, Y. Dor, T. Gorman, J. Ferrer, B. Thorens, F. Reimann, F. Gribble, J. A. McGinty, L. Chen, P. M. French, F. Birzele, T. Hildebrandt, I. Uphues and G. A. Rutter (2014). "LKB1 and AMPK differentially regulate pancreatic beta-cell identity." *FASEB J* **28**(11): 4972-4985.

Laforet, P., P. Richard, M. A. Said, N. B. Romero, E. Lacene, J. P. Leroy, C. Baussan, J. Y. Hogrel, T. Lavergne, K. Wahbi, B. Hainque and D. Duboc (2006). "A new mutation in PRKAG2 gene causing hypertrophic cardiomyopathy with conduction system disease and muscular glycogenosis." Neuromuscul Disord **16**(3): 178-182.

Lai, Y. C., S. Kviklyte, D. Vertommen, L. Lantier, M. Foretz, B. Viollet, S. Hallen and M. H. Rider (2014). "A small-molecule benzimidazole derivative that potently activates AMPK to increase glucose transport in skeletal muscle: comparison with effects of contraction and other AMPK activators." The Biochemical journal **460**(3): 363-375.

Lantier, L., J. Fentz, R. Mounier, J. Leclerc, J. T. Treebak, C. Pehmoller, N. Sanz, I. Sakakibara, E. Saint-Amand, S. Rimbaud, P. Maire, A. Marette, R. Ventura-Clapier, A. Ferry, J. F. Wojtaszewski, M. Foretz and B. Viollet (2014). "AMPK controls exercise endurance, mitochondrial oxidative capacity, and skeletal muscle integrity." FASEB J **28**(7): 3211-3224.

Lee, H., J. S. Cho, N. Lambacher, J. Lee, S. J. Lee, T. H. Lee, A. Gartner and H. S. Koo (2008). "The *Caenorhabditis elegans* AMP-activated protein kinase AAK-2 is phosphorylated by LKB1 and is required for resistance to oxidative stress and for normal motility and foraging behavior." The Journal of biological chemistry **283**(22): 14988-14993.

Lee, J. H., H. Koh, M. Kim, Y. Kim, S. Y. Lee, R. E. Karess, S. H. Lee, M. Shong, J. M. Kim, J. Kim and J. Chung (2007). "Energy-dependent regulation of cell structure by AMP-activated protein kinase." Nature **447**(7147): 1017-1020.

Lee-Young, R. S., S. R. Griffiee, S. E. Lynes, D. P. Bracy, J. E. Ayala, O. P. McGuinness and D. H. Wasserman (2009). "Skeletal muscle AMP-activated protein kinase is essential for the metabolic response to exercise in vivo." The Journal of biological chemistry **284**(36): 23925-23934.

Li, F. Y., K. S. Lam, H. F. Tse, C. Chen, Y. Wang, P. M. Vanhoutte and A. Xu (2012). "Endothelium-selective activation of AMP-activated protein kinase prevents diabetes mellitus-induced impairment in vascular function and reendothelialization via induction of heme oxygenase-1 in mice." Circulation **126**(10): 1267-1277.

Lieberthal, W., M. Tang, L. Zhang, B. Viollet, V. Patel and J. S. Levine (2013). "Susceptibility to ATP depletion of primary proximal tubular cell cultures derived from

mice lacking either the alpha1 or the alpha2 isoform of the catalytic domain of AMPK." BMC Nephrol **14**: 251.

Lindgren, K., M. Ormestad, M. Persson, S. Martinsson, L. T. Svensson and M. Mahlapuu (2007). "Regulation of the muscle-specific AMP-activated protein kinase alpha2beta2gamma3 complexes by AMP and implications of the mutations in the gamma3-subunit for the AMP dependence of the enzyme." FEBS J **274**(11): 2887-2896.

Lippai, M., G. Csikos, P. Maroy, T. Lukacsovich, G. Juhasz and M. Sass (2008). "SNF4Agamma, the Drosophila AMPK gamma subunit is required for regulation of developmental and stress-induced autophagy." Autophagy **4**(4): 476-486.

Liu, Y., R. Bai, L. Wang, C. Zhang, R. Zhao, D. Wan, X. Chen, G. Caceres, D. Barr, H. Barajas-Martinez, C. Antzelevitch and D. Hu (2013). "Identification of a novel de novo mutation associated with PRKAG2 cardiac syndrome and early onset of heart failure." PLoS One **8**(5): e64603.

Loffler, A. S., S. Alers, A. M. Dieterle, H. Keppeler, M. Franz-Wachtel, M. Kundu, D. G. Campbell, S. Wesselborg, D. R. Alessi and B. Stork (2011). "Ulk1-mediated phosphorylation of AMPK constitutes a negative regulatory feedback loop." Autophagy **7**(7): 696-706.

Luptak, I., M. Shen, H. He, M. F. Hirshman, N. Musi, L. J. Goodyear, J. Yan, H. Wakimoto, H. Morita, M. Arad, C. E. Seidman, J. G. Seidman, J. S. Ingwall, J. A. Balschi and R. Tian (2007). "Aberrant activation of AMP-activated protein kinase remodels metabolic network in favor of cardiac glycogen storage." The Journal of clinical investigation **117**(5): 1432-1439.

Maarbjerg, S. J., S. B. Jorgensen, A. J. Rose, J. Jeppesen, T. E. Jensen, J. T. Treebak, J. B. Birk, P. Schjerling, J. F. Wojtaszewski and E. A. Richter (2009). "Genetic impairment of AMPKalpha2 signaling does not reduce muscle glucose uptake during treadmill exercise in mice." American journal of physiology. Endocrinology and metabolism **297**(4): E924-934.

Mahmoud, A. D., S. Lewis, L. Juricic, U. A. Udoh, S. Hartmann, M. A. Jansen, O. A. Ogunbayo, P. Puggioni, A. P. Holmes, P. Kumar, J. Navarro-Dorado, M. Foretz, B. Viollet, M. B. Dutia, I. Marshall and A. M. Evans (2015). "AMPK Deficiency Blocks the Hypoxic

Ventilatory Response and Thus Precipitates Hypoventilation and Apnea." Am J Respir Crit Care Med.

Mair, W., I. Morantte, A. P. Rodrigues, G. Manning, M. Montminy, R. J. Shaw and A. Dillin (2011). "Lifespan extension induced by AMPK and calcineurin is mediated by CRTCL1 and CREB." Nature **470**(7334): 404-408.

Maixner, D. W., X. Yan, M. Gao, R. Yadav and H. R. Weng (2015). "Adenosine Monophosphate-activated Protein Kinase Regulates Interleukin-1beta Expression and Glial Glutamate Transporter Function in Rodents with Neuropathic Pain." Anesthesiology **122**(6): 1401-1413.

Medina, P. M., L. L. Swick, R. Andersen, Z. Blalock and J. E. Brenman (2006). "A novel forward genetic screen for identifying mutations affecting larval neuronal dendrite development in *Drosophila melanogaster*." Genetics **172**(4): 2325-2335.

Merrill, G. F., E. J. Kurth, D. G. Hardie and W. W. Winder (1997). "AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle." The American journal of physiology **273**(6 Pt 1): E1107-1112.

Milan, D., J. T. Jeon, C. Looft, V. Amarger, A. Robic, M. Thelander, C. Rogel-Gaillard, S. Paul, N. Iannuccelli, L. Rask, H. Ronne, K. Lundstrom, N. Reinsch, J. Gellin, E. Kalm, P. L. Roy, P. Chardon and L. Andersson (2000). "A mutation in PRKAG3 associated with excess glycogen content in pig skeletal muscle." Science **288**(5469): 1248-1251.

Mirouse, V., L. L. Swick, N. Kazgan, D. St Johnston and J. E. Brenman (2007). "LKB1 and AMPK maintain epithelial cell polarity under energetic stress." J Cell Biol **177**(3): 387-392.

Miura, S., Y. Kai, Y. Kamei, C. R. Bruce, N. Kubota, M. A. Febbraio, T. Kadowaki and O. Ezaki (2009). "Alpha2-AMPK activity is not essential for an increase in fatty acid oxidation during low-intensity exercise." Am J Physiol Endocrinol Metab **296**(1): E47-55.

Morita, H., H. L. Rehm, A. Meneses, B. McDonough, A. E. Roberts, R. Kucherlapati, J. A. Towbin, J. G. Seidman and C. E. Seidman (2008). "Shared genetic causes of cardiac hypertrophy in children and adults." N Engl J Med **358**(18): 1899-1908.

Mounier, R., M. Theret, L. Arnold, S. Cuvelier, L. Bultot, O. Goransson, N. Sanz, A. Ferry, K. Sakamoto, M. Foretz, B. Viollet and B. Chazaud (2013). "AMPKalpha1 regulates macrophage skewing at the time of resolution of inflammation during skeletal muscle regeneration." Cell Metab **18**(2): 251-264.

Mu, J., J. T. Brozinick, Jr., O. Valladares, M. Bucan and M. J. Birnbaum (2001). "A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle." Molecular cell **7**(5): 1085-1094.

Nakada, D., T. L. Saunders and S. J. Morrison (2010). "Lkb1 regulates cell cycle and energy metabolism in haematopoietic stem cells." Nature **468**(7324): 653-658.

Narbonne, P. and R. Roy (2006). "Inhibition of germline proliferation during C. elegans dauer development requires PTEN, LKB1 and AMPK signalling." Development (Cambridge, England) **133**(4): 611-619.

Narbonne, P. and R. Roy (2009). "Caenorhabditis elegans dauers need LKB1/AMPK to ration lipid reserves and ensure long-term survival." Nature **457**(7226): 210-214.

Ng, C. H., M. S. Guan, C. Koh, X. Ouyang, F. Yu, E. K. Tan, S. P. O'Neill, X. Zhang, J. Chung and K. L. Lim (2012). "AMP kinase activation mitigates dopaminergic dysfunction and mitochondrial abnormalities in Drosophila models of Parkinson's disease." J Neurosci **32**(41): 14311-14317.

Nilsson, E. C., Y. C. Long, S. Martinsson, S. Glund, P. Garcia-Roves, L. T. Svensson, L. Andersson, J. R. Zierath and M. Mahlapuu (2006). "Opposite transcriptional regulation in skeletal muscle of AMP-activated protein kinase gamma3 R225Q transgenic versus knock-out mice." The Journal of biological chemistry **281**(11): 7244-7252.

O'Neill, H. M., S. J. Maarbjerg, J. D. Crane, J. Jeppesen, S. B. Jorgensen, J. D. Schertzer, O. Shyroka, B. Kiens, B. J. van Denderen, M. A. Tarnopolsky, B. E. Kemp, E. A. Richter and G. R. Steinberg (2011). "AMP-activated protein kinase (AMPK) beta1beta2 muscle null mice reveal an essential role for AMPK in maintaining mitochondrial content and glucose uptake during exercise." Proc Natl Acad Sci U S A **108**(38): 16092-16097.

Obba, S., Z. Hizir, L. Boyer, D. Selimoglu-Buet, A. Pfeifer, G. Michel, M. A. Hamouda, D. Goncalves, M. Cerezo, S. Marchetti, S. Rocchi, N. Droin, T. Cluzeau, G. Robert, F. Luciano, B. Robaye, M. Foretz, B. Viollet, L. Legros, E. Solary, P. Auberger and A. Jacquel (2015). "The PRKAA1/AMPKalpha1 pathway triggers autophagy during CSF1-induced human

monocyte differentiation and is a potential target in CMML." Autophagy **11**(7): 1114-1129.

Onken, B. and M. Driscoll (2010). "Metformin induces a dietary restriction-like state and the oxidative stress response to extend *C. elegans* Healthspan via AMPK, LKB1, and SKN-1." PLoS One **5**(1): e8758.

Pan, D. A. and D. G. Hardie (2002). "A homologue of AMP-activated protein kinase in *Drosophila melanogaster* is sensitive to AMP and is activated by ATP depletion." The Biochemical journal **367**(Pt 1): 179-186.

Pehmoller, C., J. T. Treebak, J. B. Birk, S. Chen, C. Mackintosh, D. G. Hardie, E. A. Richter and J. F. Wojtaszewski (2009). "Genetic disruption of AMPK signaling abolishes both contraction- and insulin-stimulated TBC1D1 phosphorylation and 14-3-3 binding in mouse skeletal muscle." American journal of physiology. Endocrinology and metabolism **297**(3): E665-675.

Poels, J., M. R. Spasic, M. Gistelinck, J. Mutert, A. Schellens, P. Callaerts and K. K. Norga (2012). "Autophagy and phagocytosis-like cell cannibalism exert opposing effects on cellular survival during metabolic stress." Cell Death Differ **19**(10): 1590-1601.

Poirier, L., A. Shane, J. Zheng and L. Seroude (2008). "Characterization of the *Drosophila* gene-switch system in aging studies: a cautionary tale." Aging Cell **7**(5): 758-770.

Porto, A. G., F. Brun, G. M. Severini, P. Losurdo, E. Fabris, M. R. Taylor, L. Mestroni and G. Sinagra (2016). "Clinical Spectrum of PRKAG2 Syndrome." Circ Arrhythm Electrophysiol **9**(1).

Ramratnam, M., R. K. Sharma, S. D'Auria, S. J. Lee, D. Wang, X. Y. Huang and F. Ahmad (2014). "Transgenic knockdown of cardiac sodium/glucose cotransporter 1 (SGLT1) attenuates PRKAG2 cardiomyopathy, whereas transgenic overexpression of cardiac SGLT1 causes pathologic hypertrophy and dysfunction in mice." J Am Heart Assoc **3**(4).

Rockl, K. S., M. F. Hirshman, J. Brandauer, N. Fujii, L. A. Witters and L. J. Goodyear (2007). "Skeletal muscle adaptation to exercise training: AMP-activated protein kinase mediates muscle fiber type shift." Diabetes **56**(8): 2062-2069.

Rolf, J., M. Zarrouk, D. K. Finlay, M. Foretz, B. Viollet and D. A. Cantrell (2013). "AMPK α 1: a glucose sensor that controls CD8 T-cell memory." Eur J Immunol **43**(4): 889-896.

Rubin, G. M. and A. C. Spradling (1982). "Genetic transformation of Drosophila with transposable element vectors." Science **218**(4570): 348-353.

Russell, R. R., 3rd, J. Li, D. L. Coven, M. Pypaert, C. Zechner, M. Palmeri, F. J. Giordano, J. Mu, M. J. Birnbaum and L. H. Young (2004). "AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury." The Journal of clinical investigation **114**(4): 495-503.

Sag, D., D. Carling, R. D. Stout and J. Suttles (2008). "Adenosine 5'-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype." Journal of immunology **181**(12): 8633-8641.

Sayers, S., F. Reimann, F. Gribble, S. Zac-Varghese, S. R. Bloom, M. Foretz, B. Viollet and G. A. Rutter (2016). "Proglucagon promoter Cre-mediated AMPK deletion in mice increases circulating GLP-1 levels and oral glucose tolerance." PLoS One **in press**.

Schaffer, B. E., R. S. Levin, N. T. Hertz, T. J. Maures, M. L. Schoof, P. E. Hollstein, B. A. Benayoun, M. R. Banko, R. J. Shaw, K. M. Shokat and A. Brunet (2015). "Identification of AMPK Phosphorylation Sites Reveals a Network of Proteins Involved in Cell Invasion and Facilitates Large-Scale Substrate Prediction." Cell Metab **22**(5): 907-921.

Schertel, C., D. Huang, M. Bjorklund, J. Bischof, D. Yin, R. Li, Y. Wu, R. Zeng, J. Wu, J. Taipale, H. Song and K. Basler (2013). "Systematic screening of a Drosophila ORF library in vivo uncovers Wnt/Wg pathway components." Dev Cell **25**(2): 207-219.

Schonke, M., M. G. Myers, Jr., J. R. Zierath and M. Bjornholm (2015). "Skeletal muscle AMP-activated protein kinase gamma1(H151R) overexpression enhances whole body energy homeostasis and insulin sensitivity." Am J Physiol Endocrinol Metab **309**(7): E679-690.

Schulz, T. J., K. Zarse, A. Voigt, N. Urban, M. Birringer and M. Ristow (2007). "Glucose restriction extends Caenorhabditis elegans life span by inducing mitochondrial respiration and increasing oxidative stress." Cell metabolism **6**(4): 280-293.

Scott, J. W., S. A. Hawley, K. A. Green, M. Anis, G. Stewart, G. A. Scullion, D. G. Norman and D. G. Hardie (2004). "CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations." J Clin Invest **113**(2): 274-284.

Sidhu, J. S., Y. S. Rajawat, T. G. Rami, M. H. Gollob, Z. Wang, R. Yuan, A. J. Marian, F. J. DeMayo, D. Weilbacher, G. E. Taffet, J. K. Davies, D. Carling, D. S. Khoury and R. Roberts (2005). "Transgenic mouse model of ventricular preexcitation and atrioventricular reentrant tachycardia induced by an AMP-activated protein kinase loss-of-function mutation responsible for Wolff-Parkinson-White syndrome." Circulation **111**(1): 21-29.

Song, X. M., M. Fiedler, D. Galuska, J. W. Ryder, M. Fernstrom, A. V. Chibalin, H. Wallberg-Henriksson and J. R. Zierath (2002). "5-Aminoimidazole-4-carboxamide ribonucleoside treatment improves glucose homeostasis in insulin-resistant diabetic (ob/ob) mice." Diabetologia **45**(1): 56-65.

Spasic, M. R., P. Callaerts and K. K. Norga (2008). "Drosophila alicorn is a neuronal maintenance factor protecting against activity-induced retinal degeneration." J Neurosci **28**(25): 6419-6429.

Stapleton, D., K. I. Mitchelhill, G. Gao, J. Widmer, B. J. Michell, T. Teh, C. M. House, C. S. Fernandez, T. Cox, L. A. Witters and B. E. Kemp (1996). "Mammalian AMP-activated protein kinase subfamily." J Biol Chem **271**(2): 611-614.

Steinberg, G. R., H. M. O'Neill, N. L. Dzamko, S. Galic, T. Naim, R. Koopman, S. B. Jorgensen, J. Honeyman, K. Hewitt, Z. P. Chen, J. D. Schertzer, J. W. Scott, F. Koentgen, G. S. Lynch, M. J. Watt, B. J. van Denderen, D. J. Campbell and B. E. Kemp (2010). "Whole body deletion of AMP-activated protein kinase β 2 reduces muscle AMPK activity and exercise capacity." The Journal of biological chemistry **285**(48): 37198-37209.

Stenesen, D., J. M. Suh, J. Seo, K. Yu, K. S. Lee, J. S. Kim, K. J. Min and J. M. Graff (2013). "Adenosine nucleotide biosynthesis and AMPK regulate adult life span and mediate the longevity benefit of caloric restriction in flies." Cell Metab **17**(1): 101-112.

Stephenne, X., M. Foretz, N. Taleux, G. C. van der Zon, E. Sokal, L. Hue, B. Viollet and B. Guigas (2011). "Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status." Diabetologia **54**(12): 3101-3110.

Sun, G., G. da Silva Xavier, T. Gorman, C. Priest, A. Solomou, D. J. Hodson, M. Foretz, B. Viollet, P. L. Herrera, H. Parker, F. Reimann, F. M. Gribble, S. Migrenne, C. Maignan, A.

Marley and G. A. Rutter (2015). "LKB1 and AMPKalpha1 are required in pancreatic alpha cells for the normal regulation of glucagon secretion and responses to hypoglycemia." Mol Metab **4**(4): 277-286.

Sun, G., A. I. Tarasov, J. McGinty, A. McDonald, G. da Silva Xavier, T. Gorman, A. Marley, P. M. French, H. Parker, F. Gribble, F. Reimann, O. Prendiville, R. Carzaniga, B. Viollet, I. Leclerc and G. A. Rutter (2010). "Ablation of AMP-activated protein kinase alpha1 and alpha2 from mouse pancreatic beta cells and RIP2.Cre neurons suppresses insulin release in vivo." Diabetologia **53**(5): 924-936.

Sung, M. M., B. N. Zordoky, A. L. Bujak, J. S. Lally, D. Fung, M. E. Young, S. Horman, E. J. Miller, P. E. Light, B. E. Kemp, G. R. Steinberg and J. R. Dyck (2015). "AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism." Cardiovasc Res **107**(2): 235-245.

Swick, L. L., N. Kazgan, R. U. Onyenwoke and J. E. Brenman (2013). "Isolation of AMP-activated protein kinase (AMPK) alleles required for neuronal maintenance in *Drosophila melanogaster*." Biol Open **2**(12): 1321-1323.

Tamas, P., S. A. Hawley, R. G. Clarke, K. J. Mustard, K. Green, D. G. Hardie and D. A. Cantrell (2006). "Regulation of the energy sensor AMP-activated protein kinase by antigen receptor and Ca²⁺ in T lymphocytes." J Exp Med **203**(7): 1665-1670.

Thornton, C., M. A. Snowden and D. Carling (1998). "Identification of a novel AMP-activated protein kinase beta subunit isoform that is highly expressed in skeletal muscle." J Biol Chem **273**(20): 12443-12450.

Tohyama, D. and A. Yamaguchi (2010). "A critical role of SNF1A/dAMPKalpha (*Drosophila* AMP-activated protein kinase alpha) in muscle on longevity and stress resistance in *Drosophila melanogaster*." Biochem Biophys Res Commun **394**(1): 112-118.

Tower, J. (2000). "Transgenic methods for increasing *Drosophila* life span." Mech Ageing Dev **118**(1-2): 1-14.

Trebbak, J. T., S. Glund, A. Deshmukh, D. K. Klein, Y. C. Long, T. E. Jensen, S. B. Jorgensen, B. Viollet, L. Andersson, D. Neumann, T. Wallimann, E. A. Richter, A. V. Chibalin, J. R. Zierath and J. F. Wojtaszewski (2006). "AMPK-mediated AS160 phosphorylation in

skeletal muscle is dependent on AMPK catalytic and regulatory subunits." Diabetes **55**(7): 2051-2058.

Tschape, J. A., C. Hammerschmied, M. Muhlig-Versen, K. Athenstaedt, G. Daum and D. Kretzschmar (2002). "The neurodegeneration mutant lochrig interferes with cholesterol homeostasis and Appl processing." The EMBO journal **21**(23): 6367-6376.

Tullet, J. M., C. Araiz, M. J. Sanders, C. Au, A. Benedetto, I. Papatheodorou, E. Clark, K. Schmeisser, D. Jones, E. F. Schuster, J. M. Thornton and D. Gems (2014). "DAF-16/FoxO directly regulates an atypical AMP-activated protein kinase gamma isoform to mediate the effects of insulin/IGF-1 signaling on aging in *Caenorhabditis elegans*." PLoS genetics **10**(2): e1004109.

Ulgherait, M., A. Rana, M. Rera, J. Graniel and D. W. Walker (2014). "AMPK modulates tissue and organismal aging in a non-cell-autonomous manner." Cell Rep **8**(6): 1767-1780.

Vichaiwong, K., S. Purohit, D. An, T. Toyoda, N. Jessen, M. F. Hirshman and L. J. Goodyear (2010). "Contraction regulates site-specific phosphorylation of TBC1D1 in skeletal muscle." Biochem J **431**(2): 311-320.

Viollet, B., F. Andreelli, S. B. Jorgensen, C. Perrin, A. Geloën, D. Flamez, J. Mu, C. Lenzner, O. Baud, M. Bennoun, E. Gomas, G. Nicolas, J. F. Wojtaszewski, A. Kahn, D. Carling, F. C. Schuit, M. J. Birnbaum, E. A. Richter, R. Burcelin and S. Vaulont (2003). "The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity." J Clin Invest **111**(1): 91-98.

Viollet, B., Y. Athes, R. Mounier, B. Guigas, E. Zarrinpashneh, S. Horman, L. Lantier, S. Hebrard, J. Devin-Leclerc, C. Beauvoys, M. Foretz, F. Andreelli, R. Ventura-Clapier and L. Bertrand (2009). "AMPK: Lessons from transgenic and knockout animals." Front Biosci (Landmark Ed) **14**: 19-44.

Wang, S., G. L. Dale, P. Song, B. Viollet and M. H. Zou (2010). "AMPKalpha1 deletion shortens erythrocyte life span in mice: role of oxidative stress." J Biol Chem **285**(26): 19976-19985.

Wang, S., X. Liang, Q. Yang, X. Fu, C. J. Rogers, M. Zhu, B. D. Rodgers, Q. Jiang, M. V. Dodson and M. Du (2015). "Resveratrol induces brown-like adipocyte formation in white fat

through activation of AMP-activated protein kinase (AMPK) alpha1." Int J Obes (Lond) **39**(6): 967-976.

Winder, W. W. and D. G. Hardie (1996). "Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise." The American journal of physiology **270**(2 Pt 1): E299-304.

Winder, W. W. and D. G. Hardie (1999). "AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes." Am J Physiol **277**(1 Pt 1): E1-10.

Wojtaszewski, J. F., P. Nielsen, B. F. Hansen, E. A. Richter and B. Kiens (2000). "Isoform-specific and exercise intensity-dependent activation of 5'-AMP-activated protein kinase in human skeletal muscle." The Journal of physiology **528 Pt 1**: 221-226.

Wolf, C. M., M. Arad, F. Ahmad, A. Sanbe, S. A. Bernstein, O. Toka, T. Konno, G. Morley, J. Robbins, J. G. Seidman, C. E. Seidman and C. I. Berul (2008). "Reversibility of PRKAG2 glycogen-storage cardiomyopathy and electrophysiological manifestations." Circulation **117**(2): 144-154.

Wu, J., D. Puppala, X. Feng, M. Monetti, A. L. Lapworth and K. F. Geoghegan (2013). "Chemoproteomic analysis of intertissue and interspecies isoform diversity of AMP-activated protein kinase (AMPK)." J Biol Chem **288**(50): 35904-35912.

Wu, Y., P. Song, W. Zhang, J. Liu, X. Dai, Z. Liu, Q. Lu, C. Ouyang, Z. Xie, Z. Zhao, X. Zhuo, B. Viollet, M. Foretz, J. Wu, Z. Yuan and M. H. Zou (2015). "Activation of AMPKalpha2 in adipocytes is essential for nicotine-induced insulin resistance in vivo." Nat Med **21**(4): 373-382.

Xing, Y., N. Musi, N. Fujii, L. Zou, I. Luptak, M. F. Hirshman, L. J. Goodyear and R. Tian (2003). "Glucose metabolism and energy homeostasis in mouse hearts overexpressing dominant negative alpha2 subunit of AMP-activated protein kinase." The Journal of biological chemistry **278**(31): 28372-28377.

Yang, C., Z. Li, P. Lai, X. Bai and D. Jin (2016). "Chondrocyte-Specific Ablation of AMPKalpha1 Does Not Affect Bone Development or Pathogenesis of Osteoarthritis in Mice." DNA Cell Biol.

Yang, J., S. Maika, L. Craddock, J. A. King and Z. M. Liu (2008). "Chronic activation of AMP-activated protein kinase- α 1 in liver leads to decreased adiposity in mice." Biochem Biophys Res Commun **370**(2): 248-253.

Yang, S., L. H. Long, D. Li, J. K. Zhang, S. Jin, F. Wang and J. G. Chen (2015). "beta-Guanidinopropionic acid extends the lifespan of *Drosophila melanogaster* via an AMP-activated protein kinase-dependent increase in autophagy." Aging Cell **14**(6): 1024-1033.

Yavari, A., C. J. Stocker, S. Ghaffari, E. T. Wargent, V. Steeples, G. Czibik, K. Pinter, M. Bellahcene, A. Woods, P. B. Martinez de Morentin, C. Cansell, B. Y. Lam, A. Chuster, K. Petkevicius, M. S. Nguyen-Tu, A. Martinez-Sanchez, T. J. Pullen, P. L. Oliver, A. Stockenhuber, C. Nguyen, M. Lazdam, J. F. O'Dowd, P. Harikumar, M. Toth, C. Beall, T. Kyriakou, J. Parnis, D. Sarma, G. Katritsis, D. D. Wortmann, A. R. Harper, L. A. Brown, R. Willows, S. Gandra, V. Poncio, M. J. de Oliveira Figueiredo, N. R. Qi, S. N. Peirson, R. J. McCrimmon, B. Gereben, L. Tretter, C. Fekete, C. Redwood, G. S. Yeo, L. K. Heisler, G. A. Rutter, M. A. Smith, D. J. Withers, D. Carling, E. B. Sternick, J. R. Arch, M. A. Cawthorne, H. Watkins and H. Ashrafian (2016). "Chronic Activation of gamma2 AMPK Induces Obesity and Reduces beta Cell Function." Cell Metab.

Yu, H., M. F. Hirshman, N. Fujii, J. M. Pomerleau, L. E. Peter and L. J. Goodyear (2006). "Muscle-specific overexpression of wild type and R225Q mutant AMP-activated protein kinase gamma3-subunit differentially regulates glycogen accumulation." American journal of physiology **291**(3): E557-565.

Zhang, B. L., R. L. Xu, J. Zhang, X. X. Zhao, H. Wu, L. P. Ma, J. Q. Hu, J. L. Zhang, Z. Ye, X. Zheng and Y. W. Qin (2013). "Identification and functional analysis of a novel PRKAG2 mutation responsible for Chinese PRKAG2 cardiac syndrome reveal an important role of non-CBS domains in regulating the AMPK pathway." J Cardiol **62**(4): 241-248.

Zhang, B. L., Z. Ye, R. L. Xu, X. H. You, Y. W. Qin, H. Wu, J. Cao, J. L. Zhang, X. Zheng and X. X. Zhao (2014). "Overexpression of G100S mutation in PRKAG2 causes Wolff-Parkinson-White syndrome in zebrafish." Clin Genet **86**(3): 287-291.

Zhu, Y. P., J. R. Brown, D. Sag, L. Zhang and J. Suttles (2015). "Adenosine 5'-monophosphate-activated protein kinase regulates IL-10-mediated anti-inflammatory signaling pathways in macrophages." J Immunol **194**(2): 584-594.

Zong, H., J. M. Ren, L. H. Young, M. Pypaert, J. Mu, M. J. Birnbaum and G. I. Shulman (2002). "AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation." Proceedings of the National Academy of Sciences of the United States of America **99**(25): 15983-15987.

Zou, L., M. Shen, M. Arad, H. He, B. Lofgren, J. S. Ingwall, C. E. Seidman, J. G. Seidman and R. Tian (2005). "N488I mutation of the gamma2-subunit results in bidirectional changes in AMP-activated protein kinase activity." Circ Res **97**(4): 323-328.

Table 1. Genetically modified mouse models for the study of AMPK signaling pathway.

Knock-out and floxed mice			
<i>Targeted gene</i>	<i>Genetic modification</i>	<i>Viability</i>	<i>References</i>
AMPKα1	AMPK α 1 ^{-/-}	Viable	(Jorgensen et al. 2004)
AMPKα2	AMPK α 2 ^{-/-}	Viable	(Viollet et al. 2003)
AMPKα1/α2	AMPK α 1 ^{-/-} α 2 ^{-/-}	Embryonic lethal	unpublished data
AMPKα1	AMPK α 1 ^{fl/fl}	Viable	(Nakada et al. 2010, Lantier et al. 2014)
AMPKα2	AMPK α 2 ^{fl/fl}	Viable	(Viollet et al. 2003, Nakada et al. 2010)
AMPKβ1	AMPK β 1 ^{-/-}	Viable/ postnatal death	(Dasgupta and Milbrandt 2009, Dzamko et al. 2010)
AMPKβ2	AMPK β 2 ^{-/-}	Viable	(Steinberg et al. 2010, Dasgupta et al. 2012)
AMPKβ1/β2	AMPK β 1 ^{-/-} β 2 ^{-/-}	Embryonic lethal	(O'Neill et al. 2011)
AMPKβ1	AMPK β 1 ^{fl/fl}	Viable	(O'Neill et al. 2011)
AMPKβ2	AMPK β 2 ^{fl/fl}	Viable	(O'Neill et al. 2011)
AMPKγ1	AMPK γ 1 ^{-/-}	Viable	(Foretz et al. 2011)
AMPKγ1	AMPK γ 1 ^{fl/fl}	Viable	(Foretz et al. 2011)
AMPKγ3	AMPK γ 3 ^{-/-}	Viable	(Barnes et al. 2004)
Knock-in mice			
<i>Targeted gene</i>	<i>Genetic modification</i>	<i>Phenotype</i>	<i>References</i>
AMPKγ2	AMPKγ2^{R299Q}	obesity, hyperphagia, and impaired insulin secretion	(Yavari et al. 2016)
Transgenic mice			
<i>Transgene</i>	<i>Targeted tissue</i>	<i>Promoter</i>	<i>References</i>

<i>AMPKα1^{K45R}</i>	Skeletal and cardiac muscle cells	MCK promoter/enhancer	(Fujii et al. 2005)
<i>AMPKα1^{D157A}</i>	Skeletal muscle	HSA promoter	(Miura et al. 2009)
<i>AMPKα1¹⁻³¹²</i>	Vascular endothelium	VE-cadherin promoter	(Li et al. 2012)
<i>AMPKα1^{1-312/T172D}</i>	Hepatocytes	human ApoE promoter	(Yang et al. 2008)
<i>AMPKα1^{1-312/T172D}</i>	Pancreatic β cells	RIP2 promoter	(Sun et al. 2010)
<i>AMPKα2</i>	Ubiquitous	CMV promoter	(Gong et al. 2011)
<i>AMPKα2^{K45R}</i>	Skeletal and cardiac muscle cells	MCK promoter/enhancer	(Mu et al. 2001)
<i>AMPKα2^{D157A}</i>	Skeletal and cardiac muscle cells	MCK promoter/enhancer	(Fujii et al. 2005)
<i>AMPKα2^{D157A}</i>	Pancreatic β cells	RIP2 promoter	(Sun et al. 2010)
<i>AMPKα2^{D157A}</i>	Cardiomyocytes	α -MHC promoter	(Xing et al. 2003)
<i>AMPKγ1^{R70Q}</i>	Skeletal muscle cells	α -actin promoter	(Barre et al. 2007)
<i>AMPKγ1^{H151R}</i>	Skeletal muscle cells	MLC1 promoter/enhancer	(Schonke et al. 2015)
<i>AMPKγ2</i>	Cardiomyocytes	α -MHC promoter	(Arad et al. 2003, Sidhu et al. 2005)
<i>AMPKγ2^{R302Q}</i>	Cardiomyocytes	α -MHC promoter	(Sidhu et al. 2005, Folmes et al. 2009)
<i>AMPKγ2^{N488I}</i>	Cardiomyocytes	α -MHC promoter α -MHC promoter/ tTA (Tet-off)	(Arad et al. 2003, Luptak et al. 2007) (Wolf et al. 2008)
<i>AMPKγ2^{T400N}</i>	Cardiomyocytes	α -MHC promoter	(Banerjee et al. 2007)
<i>AMPKγ2^{R531G}</i>	Cardiomyocytes	α -MHC promoter	(Davies et al. 2006)
<i>AMPKγ3</i>	Skeletal and cardiac muscle cells	MCK promoter/enhancer MLC1 promoter/enhancer	(Yu et al. 2006) (Barnes et al. 2004)
<i>AMPKγ3^{R225Q}</i>	Skeletal and cardiac muscle cells	MCK promoter/enhancer MLC1 promoter/enhancer	(Yu et al. 2006) (Barnes et al. 2004)
Tissue-specific deletion of AMPK subunits			
<i>Targeted gene</i>	<i>Targeted tissue</i>	<i>Cre-driven recombination</i>	<i>References</i>
<i>AMPKα1</i>	T cells	CD4-Cre	(Rolf et al. 2013)
	Myeloid cells	LysM-Cre	(Mounier et

			al. 2013)
	Chondrocytes	Col2 α 1-Cre	(Yang et al. 2016)
	White adipose tissue stromal vascular cells (<i>in vitro</i> deletion)	Gt(ROSA)26Sor-Cre tamoxifen-inducible	(Wang et al. 2015)
	Central nervous system	hGFAP-Cre	(Maixner et al. 2015)
	Muscle satellite cells	Pax7-Cre tamoxifen-inducible	(Fu et al. 2015, Fu et al. 2016)
	Adipocytes	Adipoq-Cre	(Wu et al. 2015)
AMPKα2	Hepatocytes	Alfp-Cre	(Andreelli et al. 2006)
	Hypothalamus AgRP neurons	AgRP-Cre	(Claret et al. 2007)
	Hypothalamus POMC neurons	POMC-Cre	(Claret et al. 2007)
	Endothelial cells	VE-cadherin-Cre	(Kohlstedt et al. 2013)
	Adipocytes	Adipoq-Cre	(Wu et al. 2015)
AMPKα1/α2	Hypothalamus POMC neurons	POMC-Cre	(Claret et al. 2007)
	Skeletal muscle cells	HSA-Cre	(Lantier et al. 2014)
	Hepatocytes	Alfp-Cre	(Guigas et al. 2006, Foretz et al. 2010)
	Pancreatic β cells	RIP2-Cre	(Sun et al. 2010)
	Pancreatic β cells	mIns1-Cre	(Kone et al. 2014)
	Pancreatic α cells	PPG-Cre	(Sun et al. 2015)
	Catecholaminergic cells	TH-Cre	(Mahmoud et al. 2015)
	Muscle satellite cells (<i>in vitro</i> deletion)	Gt(ROSA)26Sor-Cre (tamoxifen-inducible)	(Fu et al. 2013)
	Haematopoietic stem cells	Mx1-Cre (pIpC inducible)	(Nakada et al. 2010)
	proglucagon-expressing cells	proglucagon-Cre	(Sayers et al. 2016)
AMPKβ1	Skeletal and heart muscle cells	MCK-Cre	(O'Neill et al. 2011, Sung et al. 2015)
AMPKβ2	Skeletal and heart muscle cells	MCK-Cre	(O'Neill et al. 2011, Sung et al. 2015)

<i>AMPKβ1/β2</i>	Skeletal and heart muscle cells	MCK-Cre	(O'Neill et al. 2011, Sung et al. 2015)
--	---------------------------------	---------	---

Adipoq, adiponectin; AgRP, agouti-related protein; Alfp, albumin/ α -fetoprotein; ApoE, apolipoprotein E; CMV, cytomegalovirus; Col2 α 1, collagen type 2 α 1; hGFAP, human glial fibrillary acidic protein; HSA, human α -skeletal actin; Ins1, mouse insulin 1; LysM, lysozyme M; MCK, muscle creatine kinase; MLC1, myosin light chain 1; α -MHC, α -myosin heavy chain; Mx1, myxovirus resistance protein 1; Pax7, paired box-containing 7; plpC, polyinosine-polycytidine; POMC, pro-opiomelanocortin; PPG, preproglucagon; RIP2, rat insulin promoter 2; TH, tyrosine hydroxylase; tTA, Tetracycline-controlled transcriptional activator system; VE, vascular endothelial.

Table 2. Metabolic pathways dysregulated in transgenic mice overexpressing AMPK α and γ mutations in skeletal and cardiac muscles.

Organ	Pathway/function	Transgenic mice	References
Heart	Glycogen storage cardiomyopathy	AMPK γ 2 ^{R302Q} AMPK γ 2 ^{N488I} AMPK γ 2 ^{R531G} AMPK γ 2 ^{T400N}	(Sidhu et al. 2005) (Arad et al. 2003, Luptak et al. 2007) (Davies et al. 2006) (Banerjee et al. 2007)
	Ischemic/post-ischemic tolerance	AMPK α 2 ^{R45A} AMPK α 2 ^{D157A}	(Russell et al. 2004) (Xing et al. 2003)
	Glucose transport, glycogen metabolism, glycolysis	AMPK α 2 ^{R45A} AMPK α 2 ^{D157A}	(Xing et al. 2003, Russell et al. 2004)
	Mitochondrial biogenesis/ function	AMPK α 2 ^{D157A}	(Gundewar et al. 2009)
Skeletal muscle	Glucose transport	AMPK α 2 ^{R45A} AMPK α 2 ^{D157A}	(Mu et al. 2001) (Xing et al. 2003)
	Contraction/exercise tolerance	AMPK α 2 ^{R45A} AMPK α 2 ^{D157A} AMPK γ 1 ^{R70Q} AMPK γ 3 ^{R225Q}	(Mu et al. 2001) (Fujii et al. 2007, Rockl et al. 2007) (Barre et al. 2007, Rockl et al. 2007) (Barnes et al. 2004, Barnes et al. 2005)
	Glycogen metabolism	AMPK γ 3 ^{R225Q} AMPK γ 1 ^{R70Q}	(Barnes et al. 2004, Yu et al. 2006) (Barre et al. 2007)
	Mitochondrial biogenesis/ function	AMPK α 2 ^{R45A}	(Zong et al. 2002)

Table 3. AMPK mutations in *Drosophila*.

Gene	Allele	description	mutagenesis	References
<i>dAMPKα</i>	AMPK α^{D1}	Deletion 1,268,785–1,270,743 bp	Imprecise excision P-element	(Lee et al. 2007, Schertel et al. 2013)
	AMPK α^{D2}	Deletion 1,269,080–1,270,246 bp	Imprecise excision P-element	
	AMPK α^1 AMPK α^2	Amino acid replacement (Y141) Amino acid replacement (S211L)	EMS mutagenesis EMS mutagenesis	(Mirouse et al. 2007) www.flybase.org www.flybase.org
<i>dAMPKβ</i> <i>alicorn</i> <i>(alc)</i>	$\Delta 12.125$	Deletion of 1718 bp (nonsense point mutation replacing codon 233/112 in <i>alc</i> transcripts RA/RB)	Imprecise excision P-element	(Spasic et al. 2008)
	<i>l(2)45Ad²</i>		EMS mutagenesis	(Dockendorff et al. 2000)
<i>dAMPKγ</i> <i>loechrig</i> <i>(loe)</i>	<i>loechrig</i>	P-element insertion	P-element insertion	(Deak et al. 1997, Tschape et al. 2002)

Table 4. Transgenic *Drosophila* for the study of AMPK signaling pathway.

Gene	Allele	description	References
dAMPKα	AMPK α ^{WT.Scer\UAS}	Wilt-type AMPK α	(Lee et al. 2007, Schertel et al. 2013)
	AMPK α ^{KR.Scer\UAS}	Kinase-dead form of AMPK α	(Lee et al. 2007)
	AMPK α ^{K56R.Scer\UAS}	Kinase dead version of AMPK α with a K56R amino acid substitution	(Bland et al. 2010)
	AMPK α ^{K57A.Scer\UAS}	Kinase dead version of AMPK α with a K57A amino acid substitution	(Johnson et al. 2010, Stenesen et al. 2013)
	AMPK α ^{TD.Scer\UAS}	Constitutively active form of AMPK α	(Lee et al. 2007)
	AMPK α ^{T184D.Scer\UAS}	Constitutively active form of AMPK α	(Mirouse et al. 2007)
	Scer\UAS- AMPK α ^{RNAi}	AMPK α RNAi	(Dietzl et al. 2007)
	AMPK α ^{Scer\UAS.T:Avic\GFP}	AMPK α GFP-tagged at the N-terminal end	(Kazgan et al. 2010)
	AMPK α ^{Scer\UAS.ORF.T:Ivir\HA1}	Full-length AMPK α tagged at the C-terminal end with three copies of HA	(Schertel et al. 2013)
	AMPK α ^{ΔC.Scer\UAS.T:Disc\RFP-mCherry}	Truncated form of AMPK α lacking the C-terminal 22 amino acid residues (a stop codon has been introduced after Pro561) tagged at the N-terminal end with mCherry	(Mirouse et al. 2007)
	AMPK α ^{Scer\UAS.T:Disc\RFP-mCherry}	AMPK α tagged at the N-terminal end with mCherry	(Kazgan et al. 2010)
AMPKγ loechrig (loe)	Scer\UAS- AMPK γ ^{RNAi}	Scer\UAS- AMPK γ ^{RNAi}	(Johnson et al. 2010)

Table 5. AMPK mutant strains for the study of AMPK signaling pathway in *C. elegans*.

Gene	Allele	description	References
aak	<i>aak-1(tm1944)</i>	Deletion of 618 bp	(Lee et al. 2008)
	<i>aak-2(ok524)</i>	Deletion of 408 bp (protein truncated after amino acid 164 lacking complete kinase domain as well as the inhibitory and AMPK β γ -binding domains)	(Apfeld et al. 2004)
	<i>aak-2(rr48)</i>	Point mutation H208Y predicted to disrupt the catalytic activity of the α subunit	(Narbonne and Roy 2006)
	<i>aak-2(gt33)</i>	Deletion of 606 bp generated by random UV-activated trimethyl-psoralen mutagenesis	(Jansen et al. 1997)
	<i>Paak-2::gfp</i>	Promoter GFP fusion	(Tullet et al. 2014)

<i>aakb</i>	<i>aakb-1(tm2658)</i>	Deletion of 146 bp (part of the glycogen-binding domain is missing)	(Narbonne and Roy 2009)
	<i>Paakb-1::gfp</i>	Promoter GFP fusion	(Tullet et al. 2014)
	<i>aakb-2(rr88)</i>	C262T transition introducing a premature stop codon	(Narbonne and Roy 2009)
<i>aakg</i>	<i>aakg-4(tm5097)</i>	Deletion of 231 bp + insertion of 24 bp	www.wormbase.org
	<i>aakg-4(tm5269)</i>	Deletion of 272 bp	www.wormbase.org
	<i>aakg-4(tm5539)</i>	Deletion of 405 bp (region encoding portions of both CBS3 and CBS4 domains)	(Tullet et al. 2014)
	<i>Paakg-4::gfp</i>	Promoter GFP fusion	(Tullet et al. 2014)
	<i>Paakg-5::gfp</i>	Promoter GFP fusion	(Tullet et al. 2014)

Figure 1: Timeline of animal models generated for the study of AMPK biology.

Deletion of the AMPK α , β and γ genes in *Caenorhabditis elegans* (*aak-1*, *aak-2*, *aakb-1* and *aakb-2*), *Drosophila melanogaster* (*dAMPK α* , *dAMPK β /Loechnig* and *dAMPK γ /Alicorn*), *mus musculus* (*AMPK α 1*, *AMPK α* , *AMPK β 1*, *AMPK β 2*, *AMPK γ 1* and *AMPK γ 3*) are shown in the upper panel. Naturally occurring mutations in the human and porcine AMPK γ gene are shown in the middle panel. Transgenic mouse and fish models expressing AMPK α and γ mutations are shown in the lower panel. Refer to Tables 1, 3 and 5 for references.

Figure 2: Diversity in the genes encoding the AMPK subunits between animal species. Schematic representation of the different genes encoding the AMPK α , AMPK β and AMPK γ subunits in *Caenorhabditis elegans* (aak-1/2, aakb-1/2 and aakg-1/2/3/4/5), *Drosophila melanogaster* (dAMPK α , dAMPK β /Loechnig and dAMPK γ /Alicorn), *mus musculus* (AMPK α 1/2, AMPK β 1/2 and AMPK γ 1/2/3) and *Homo sapiens* (AMPK α 1/2, AMPK β 1/2 and AMPK γ 1/2/3).